IGDB.NSCLC Gene View
 
Gene Information        (help)
Gene CSF3 Ensembl ENSG00000108342 Chromosome 17 Start 35425140 End 35427592
Description Granulocyte colony-stimulating factor Precursor (G-CSF)(Pluripoietin)(Filgrastim)(Lenograstim) [Source:UniProtKB/Swiss-Prot;Acc:P09919]
GENE RESOURCES :NUCLEOTIDE SEQUENCES :PROTEIN RESOURCES :CLINICAL RESOURCES :REFERENCES :
     HGNC : 2438
     Entrez Gene : 1440
     UCSC : uc002htp.2
     GeneCards : 2438
     RefSeq : NM_000759
     CCDS : CCDS11357.1
     Uniprot : P09919
     Interpro : P09919
     OMIM : 138970
     GeneTests : CSF3
     CGAP : CSF3
     PMID : 3499671

< Top >


Microarray Gene Expression Fold Change Result        (help)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background : these probesets might have mapping problems. ref 1, ref 2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U95  1334_s_at  -1.53  2.11e-10  3.00e-9  -1.62  8.98e-4  2.82e-3
 HG_U133A  207442_at  -3.05  1.57e-66  1.78e-64  -2.41  1.38e-24  2.15e-24
 HG_U133_Plus2  207442_at  -3.69  1.69e-41  4.09e-39  -4.02  1.45e-26  4.34e-25
 Agilent_HS_21.6K  14271  -0.12  5.19e-7  1.39e-5  -0.13  5.59e-9  1.82e-7

< Top >


Adjuvant Cisplatin/vinorelbine Treatment vs Observation Result        (help) (Pubmed)
( red: up-regulation / green : down-regulation when p value < 0.01)
( gray background color : the mapping problems of probeset. ref_1, ref_2)
Chip Type Probeset Adenocarcinoma Squamous Cell Carcinoma
Fold Change p value q value Fold Change p value q value
 HG_U133A  207442_at  0.29  6.01e-1  9.53e-1  0.36  2.63e-1  1.00e+0

< Top >


Microarray Sample Data        (help)
( The log2 value of tumor samples )
(Average : Average log2 value from Normal Samples.)
        HG_U95 - 1334_s_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133A - 207442_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        HG_U133_Plus2 - 207442_at    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

        Agilent_HS_21.6K - 14271    (back)       Save as a PNG file. Save as a PDF file. Save as a PS file.
Gene expression figure

< Top >


Cancer Gene Index        (help)

If 0 entry was found, please remove the search key "lung cancer".
Keyword DiseaseData Statement PubMed Organism
gcsf gall-bladder carcinoma These findings confirmed the present case of GCSF-producing gall-bladder carcinoma, exhibiting leukocytosis. 10594849 Human
gcsf gall-bladder carcinoma A total of five cases, including our case, reported as a GCSF-producing gall-bladder carcinoma were clinicopathologically reviewed. 10594849 Human
g-csf diffuse large b-cell lymphoma CASE REPORT: A 62-year old patient was diagnosed with a diffuse large B-cell lymphoma and treated with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone under prophylactic G-CSF substitution. 17341901 Human
g-csf pc-3 human prostate cancer The PEITC treatment reduced migration by PC-3 human prostate cancer cells, which correlated with inactivation of Akt and suppression of VEGF, epidermal growth factor (EGF), and granulocyte colony-stimulating factor (G-CSF) secretion. 17332354 Human
g-csf central osteosarcoma METHODS: Previously untreated patients with nonmetastatic, high-grade, central osteosarcoma of an extremity were randomly assigned to Regimen-C (conventional treatment with six 3-week cycles of cisplatin [100 mg/m2 by 24-hour infusion] and doxorubicin [25 17227995 Human
g-csf crohn's disease Peripheral blood stem cells (PBSC) were mobilized in 130 patients with autoimmune diseases undergoing autologous hematopoietic stem cell transplantation using cyclophosphamide 2 g/m(2) and either granulocyte colony-stimulating factor (G-CSF) 5 mcg/kg/day 17277794 Human
g-csf ductal adenocarcinoma of the pancreas [A case of granulocyte-colony stimulating factor producing ductal adenocarcinoma of the pancreas] We report a case of pancreatic ductal adenocarcinoma producing granulocyte-colony stimulating factor (G-CSF). 17283419 Human
g-csf pancreatic ductal adenocarcinoma [A case of granulocyte-colony stimulating factor producing ductal adenocarcinoma of the pancreas] We report a case of pancreatic ductal adenocarcinoma producing granulocyte-colony stimulating factor (G-CSF). 17283419 Human
g-csf esophageal cancer The aim of the current randomized, placebo-controlled, multicenter phase III trial was to investigate the clinical efficacy of perioperative G-CSF administration in reducing infection and mortality after esophagectomy for esophageal cancer. 15213620 Human
g-csf esophageal cancer CONCLUSION: Perioperative administration of G-CSF failed to reduce postoperative morbidity, infection rate, or mortality in patients with esophageal cancer who underwent esophagectomy. 15213620 Human
gcsf transitional cell carcinoma Based on recent Phase II data of an active regimen comprised of AG alternating with ifosfamide, paclitaxel, and cisplatin (ITP) in patients with transitional cell carcinoma, the patient was treated with ifosfamide, 1500 mg/m(2) (Days 1-3); paclitaxel, 175 11815966 Human
g-csf extensive-stage small-cell lung cancer Carboplatin plus vinorelbine plus G-CSF in elderly patients with extensive-stage small-cell lung cancer: a poorly tolerated regimen. 12009246 Human
lenograstim extensive small-cell lung cancer PURPOSE AND METHODS: A multicentre phase II trial (single-stage design) was undertaken to test the activity and toxicity of carboplatin (AUC 5 according to Calvert, day 1) plus vinorelbine (25 mg/m(2) days 1 and 8) with lenograstim support, every 3 weeks 12009246 Human
granulocyte colony stimulating factor inflammatory bowel disease Other biologic compounds for which there is insufficient evidence to judge efficacy for inflammatory bowel disease include: p55 tumor necrosis factor binding protein (onercept); interferon alpha; interferon beta-1a; anti-interferon gamma antibody; anti-in 12016425 Human
g-csf germ cell tumours Granulocyte colony-stimulating factor (G-CSF) levels were studied in 23 patients (10 myeloma, 13 relapsed Hodgkin's disease, non-Hodgkin's lymphoma or germ cell tumours), post autologous peripheral blood stem cell transplantation (PBSCT). 12028037 Human
g-csf de novo acute myeloid leukemia with multilineage dysplasia De novo acute myeloid leukemia with multilineage dysplasia: treatment results and prognostic evaluation from a series of 44 patients treated with fludarabine, cytarabine and G-CSF (FLAG). 12071935 Human
g-csf de novo acute myeloid leukemia with multilineage dysplasia OBJECTIVES: To evaluate therapeutic results and prognostic factors from a series of 44 patients affected by de novo acute myeloid leukemia with multilineage dysplasia (MD-AML), treated with the combination of fludarabine, cytarabine and G-CSF (FLAG). 12071935 Human
g-csf soft-tissue sarcoma Serum levels of 9 cytokines (TNFalpha, IL-1ra, IL-6, IL-8, IL-10, M-CSF, G-CSF, VEGF, bFGF) and 4 free cytokine receptors (sIL-2R alpha, sIL-6R, TNFRI, TNFRII) were measured by means of an enzyme-linked immunoadsorbent assay kit in 156 soft tissue sarcoma 12115531 Human
g-csf pancreatic cancer These results suggest that PMNs play an important role in c-Nd2 inducing ADCC and that combination immunotherapy of c-Nd2 with G-CSF may have clinical applications in the treatment of patients with pancreatic cancer by enhancing ADCC. 12168113 Human
g-csf rhabdomyosarcoma BACKGROUND: To increase the dose intensity (DI) of chemotherapy for pediatric patients with metastatic sarcomas, including the Ewing sarcoma family of tumors (ESFT) and rhabdomyosarcoma (RMS), the authors tested the feasibility of an intensive regimen sup 12216105 Human
filgrastim neuroendocrine tumors Phase II clinical trial of parenteral hydroxyurea in combination with fluorouracil, interferon and filgrastim in the treatment of advanced pancreatic, gastric and neuroendocrine tumors. 14704829 Human
g-csf colon cancer We show here that granulocyte colony-stimulating factor (G-CSF) markedly promotes growth of the colon cancer inoculated into the subcutaneous space of mice, whereas G-CSF had no effect on cancer cell proliferation in vitro. 12359263 Mouse
gcsf inflammatory bowel disease Patients with glycogen storage disease type 1b (GSD-1b) have neutropenia and neutrophil dysfunction that predispose to frequent infections and inflammatory bowel disease (IBD), for which granulocyte colony-stimulating factor (GCSF) is given. 12373578 Human
g-csf murine leukemia Immunotherapy of murine leukemia following non-myeloablative conditioning with naive or G-CSF mobilized blood or bone marrow stem cells. 14605765 Mouse
g-csf primary carcinomas The expression of G-CSFR was observed in the malignant cells of each of the 46 primary carcinomas examined; G-CSF was coexpressed in both the malignant epithelial cells and the stroma of 56.5% of the specimens. 11121868 Human
g-csf pediatric solid tumors PATIENTS AND METHODS: From June 1992 until November 1994, 123 patients with recurrent or refractory pediatric solid tumors were treated with ifosfamide (1,800 mg/m2 per day x 5), carboplatin (400 mg/m2 per day x 2), and etoposide (100 mg/m2 per day x 5) a 11196267 Human
g-csf gynecologic cancers PURPOSE: The primary objective of this phase I trial was to determine the feasibility of administering a combination of paclitaxel, cisplatin, and doxorubicin with or without granulocyte colony-stimulating factor (G-CSF) in patients with advanced endometr 11181665 Human
g-csf malignant mesothelioma The patient died 6 weeks after disease progression had been noted, and immunohistochemistry using a specific monoclonal antibody against recombinant G-CSF at autopsy demonstrated that the malignant mesothelioma cells actually produced G-CSF. 11243992 Human
g-csf malignant pleural mesothelioma Only three cases of malignant pleural mesothelioma, including the current patient, have been reported to produce G-CSF. 11243992 Human
g-csf aids-related lymphoma Twenty patients with biopsy-proven AIDS-related lymphoma were treated with three 6-week cycles of oral chemotherapy consisting of lomustine (CCNU) 100 mg/m2 on day 1, cycles no. 1 and 3; etoposide 200 mg/m2 days 1-3; cyclophosphamide and procarbazine both 11279624 Human
gcsf anaplastic tumor METHODS: Twenty-four patients (14 with carcinoid tumors, 9 with islet cell tumors, and 1 with an anaplastic tumor) were enrolled on this Phase II study of paclitaxel given as a 24-hour continuous infusion at a dose of 250 mg/m(2) every 3 weeks plus GCSF a 11301403 Human
gcsf islet-cell tumors METHODS: Twenty-four patients (14 with carcinoid tumors, 9 with islet cell tumors, and 1 with an anaplastic tumor) were enrolled on this Phase II study of paclitaxel given as a 24-hour continuous infusion at a dose of 250 mg/m(2) every 3 weeks plus GCSF a 11301403 Human
gcsf neuroendocrine tumors CONCLUSIONS: Given the lack of antitumor activity of paclitaxel and the significant hematologic toxicity observed despite the use of GCSF support in the current study cohort of patients with neuroendocrine tumors, further studies of this combination in th 11301403 Human
filgrastim colorectal cancer CONCLUSION: The following hypothesis will be tested in patients with operations for colorectal cancer and increased preoperative risk (ASA 3 and 4): is the outcome as evaluated by the hermeneutic endpoint (quality of life expressed by the patient) and mec 11339498 Human
g-csf pancreatic tumor These results suggest that the pancreatic tumor cells producing G-CSF were entrapped in the glomerular capillary lumina where they proliferated. 11382703 Human
g-csf head and neck carcinoma G-CSFs producing the head and neck carcinoma cell line T3M-1 cells with metastatic ability and no G-CSF receptor (G-CSFR) expression were transfected with G-CSFR expression vector. 11391619 Human
g-csf adult acute myeloid leukemia We conclude that PBSC mobilization with G-CSF alone initiated in steady state is a feasible, safe, and suitable procedure for harvesting cells in sight of autologous transplantation in adult acute myeloid leukemia. 11732869 Human
g-csf lymphoblastic lymphoma A 28-year-old man with lymphoblastic lymphoma received G-CSF mobilized stem cells from his HLA identical sister, who had been taking methotrexate for psoriasis until 1 month prior to harvest. 11851944 Human
g-csf myeloid-lymphoid leukemia METHODS: Clonal rearrangements in the gene sequences of retinoic acid receptor (RAR) alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T-cell receptor (TcR) beta, myeloid lymphoid leukemia or cytokines (GM-CSF, G-CSF, IL-3) detected 11860441 Human
g-csf metastatic disease The aim of this paper is to underline the importance of planned splenectomy in these patients even if they have metastatic disease, and to propose an intensive chemotherapy regimen consisting of anthracyclines, ifosfamide and mesna with G-CSF support. 11989602 Human
filgrastim lymphoblastic lymphoma Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. 10657867 Human
filgrastim t-cell leukemia Cost analysis of filgrastim for the prevention of neutropenia in pediatric T-cell leukemia and advanced lymphoblastic lymphoma: a case for prospective economic analysis in cooperative group trials. 10657867 Human
granulocyte colony stimulating factor adenocarcinoma of the stomach Possible paracrine growth of adenocarcinoma of the stomach induced by granulocyte colony stimulating factor produced by squamous cell carcinoma of the oesophagus. 10673310 Human
g-csf oesophageal carcinoma Whereas enzyme immunoassay of tissue extracts showed that the oesophageal carcinoma produced G-CSF, the gastric cancer did not. 10673310 Human
g-csf oesophageal cancer These findings suggest that the oesophageal cancer promoted gastric cancer growth by paracrine mechanisms involving G-CSF. 10673310 Human
g-csf wegener's granulomatosis The theoretical risk of triggering vasculitis resulting from administration of G-CSF and GM-CSF to patients with anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitides (AAV), such as Wegener's granulomatosis (WG), who develop agranulocyt 10792393 Human
filgrastim recurrent endometrial cancer Filgrastim support during combination chemotherapy using cisplatin, doxorubicin, and cyclophosphamide to treat advanced or recurrent endometrial cancer: a clinical study and literature review. 14658586 Human
g-csf chronic phase chronic myeloid leukemia We report a high incidence (50%) of side-effects associated with post-transplant G-CSF in patients with chronic phase chronic myeloid leukemia undergoing allogeneic HLA-identical sibling peripheral blood stem cell transplantation. 10849533 Human
g-csf recurrent carcinoma of the endometrium CONCLUSION: The combination of paclitaxel with cisplatin with G-CSF support appears active in patients with metastatic or recurrent carcinoma of the endometrium. 10873410 Human
g-csf adenocarcinoma PATIENTS AND METHODS: In the initial dose-escalation phase, 25 patients with adenocarcinoma of the breast (AB; 13 patients) or lymphoma (12 patients) were given daniplestim at doses ranging from 0.1 to 3.75 microgram/kg/d plus G-CSF 10 microgram/kg/d. 10894877 Human
g-csf angiosarcoma The highly elevated serum G-CSF of 303 ng L-1 (normal, 6.1-21.5 ng L-1) and positive immunohistochemical staining of the tumour tissue for G-CSF indicated that G-CSF was produced by the cutaneous angiosarcoma. 14674908 Human
g-csf choriocarcinoma The effect of G-CSF on cytotoxicity of decidual lymphocytes against the choriocarcinoma cell line JEG-3 was examined by lactate dehydrogenase (LDH) release assay. 14506932 Human
g-csf blast crisis In the present study, we demonstrated that the proliferation of leukemic cells from chronic myeloid leukemia in blast crisis (CML-BC) and Ph1-positive acute lymphoblastic leukemia (ALL) cases is frequently stimulated with G-CSF in vitro. 10942233 Human
g-csf mantle-cell lymphoma Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. 10936869 Human
g-csf myeloid-lymphoid leukemia (mll) At diagnosis, clonal gene rearrangement probes [retinoic acid receptor (RAR)-alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T cell receptor (TcR)-beta, myeloid lymphoid leukemia (MLL) or cytokine genes (GM-CSF, G-CSF, IL-3)] were 10940650 Human
g-csf pancreatic adenocarcinoma A phase II trial of etoposide, leucovorin, 5-FU, and interferon alpha 2b (ELFI) + G-CSF for patients with pancreatic adenocarcinoma: a Southwest Oncology Group study (SWOG 9413). 10958597 Human
g-csf metastatic pancreatic adenocarcinoma METHODS: Fifty-five eligible patients with locally-advanced or metastatic pancreatic adenocarcinoma received a regimen consisting of: i.v. leucovorin at 300 mg/m2/day on Days 1-3 (of 28-day cycle), i.v. etoposide at 80 mg/m2/day on Days 1-3, i.v. 5-FU at 10958597 Human
filgrastim laryngeal carcinoma Hyperfractionated radiotherapy concomitant with cisplatin and granulocyte colony-stimulating factor (filgrastim) for laryngeal carcinoma. 10976537 Human
filgrastim laryngeal carcinoma An open-label, non-randomized study evaluated the feasibility and efficacy of filgrastim (recombinant methionyl human granulocyte colony-stimulating factor, r-metHuG-CSF) to prevent mucositis induced by accelerated hyperfractionated radiotherapy (1.6 Gy b 10976537 Human
g-csf cervical cancer A case of cervical cancer with aggressive tumor growth: possible autocrine growth stimulation by G-CSF and Il-6. 10985899 Human
g-csf cervical cancer CONCLUSIONS: This is a case of cervical cancer which exhibited an aggressive clinical course, possibly due to autocrine stimulation of cell growth by G-CSF and IL-6. 10985899 Human
g-csf pediatric solid tumors To the authors' knowledge, no large study has focused on G-CSF in this setting, yet this kind of treatment has recently become standard for poor risk pediatric solid tumors such as neuroblastoma. 11066054 Human
g-csf murine leukemia We have reported that murine leukemia cell line (C2M-A5) induced apoptosis by G-CSF. 11077117 Mouse
g-csf adult t-cell leukaemia We previously demonstrated that, in about 30% of primary adult T-cell leukaemia (ATL) cases, the leukaemic cells proliferated in response to granulocyte colony-stimulating factor (G-CSF). 11091203 Human
g-csf esophageal cancer Increase of anti-inflammatory cytokines in patients with esophageal cancer after perioperative treatment with G-CSF. 11097751 Human
g-csf blast crisis Six relapsed acute lymphoblastic leukemia (ALL), nine relapsed acute myeloblastic leukemia (AML), one chronic myelomonocytic leukemia (CMML) and one chronic myeloid leukemia (CML) in acute blast crisis between three to 18 years (median 10 years) received 11105617 Human
g-csf malignant fibrous histiocytoma G-CSF producing malignant fibrous histiocytoma in the jejunum: a case report. 11149020 Human
g-csf lymphoma Untreated patients with aggressive lymphoma under the age of 60 with two or three adverse prognostic factors (disseminated stage, increased serum LDH, ECOG performance status >1) were prospectively included between June 1995 and April 1998 in a trial eval 11187906 Human
g-csf thyroid carcinoma We measured the concentrations of granulocyte colony-stimulating factor (G-CSF), macrophage CSF (M-CSF), granulocyte-macrophage CSF (GM-CSF), interleukin-1alpha (IL-1alpha), IL-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) in sera, pleural effu 11201858 Human
g-csf cyst We measured the concentrations of granulocyte colony-stimulating factor (G-CSF), macrophage CSF (M-CSF), granulocyte-macrophage CSF (GM-CSF), interleukin-1alpha (IL-1alpha), IL-1beta, IL-6, and tumor necrosis factor-alpha (TNF-alpha) in sera, pleural effu 11201858 Human
g-csf medullary thyroid cancer Nine radioimmunotherapy (RAIT)-naive patients with medullary thyroid cancer received high doses of 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody (232-486 mCi), five in combination with bone marrow harvest, without prior granulocyte c 10541383 Human
granulocyte colony stimulating factor medullary thyroid cancer Nine radioimmunotherapy (RAIT)-naive patients with medullary thyroid cancer received high doses of 131I-MN-14 F(ab)2 anti-carcinoembryonic antigen monoclonal antibody (232-486 mCi), five in combination with bone marrow harvest, without prior granulocyte c 10541383 Human
g-csf glioblastoma The implication of G-CSF and GM-CSF in glioblastoma growth regulation could make these factors further prognostic indicators and raises questions concerning their use in cancer therapy. 10550313 Human
g-csf cancer The implication of G-CSF and GM-CSF in glioblastoma growth regulation could make these factors further prognostic indicators and raises questions concerning their use in cancer therapy. 10550313 Human
gcsf gall-bladder carcinoma Primary gall-bladder carcinoma producing granulocyte-colony stimulating factor (GCSF) is extremely rare. 10594849 Human
gcsf gall-bladder carcinoma We report a case of a 48-year-old female with primary gall-bladder carcinoma, associating with leukocytosis (15 700/mm3) and a high level of serum GCSF (54.0 pg/mL). 10594849 Human
g-csf skin carcinoma Constitutive expression of G-CSF and GM-CSF in human skin carcinoma cells with functional consequence for tumor progression. 10597195 Human
g-csf skin carcinoma In the human skin carcinoma model system, based on the HaCaT keratinocyte line, tumor progression to high-grade malignant cells is associated with constitutive expression and secretion of the hematopoietic growth factors G-CSF and GM-CSF in vitro and in v 10597195 Human
g-csf inflammatory breast cancer OBJECTIVE: The aim of the study was to investigate a dose-intensified, preoperative chemotherapy with 3 cycles (cy) of epirubicin 60 mg/m2, ifosfamide 5 g/m2 with mesna 5 g/m2, biweekly with G-CSF 5 micrograms/kg (filgrastim), in terms of toxicity, clinic 10612219 Human
filgrastim inflammatory breast cancer OBJECTIVE: The aim of the study was to investigate a dose-intensified, preoperative chemotherapy with 3 cycles (cy) of epirubicin 60 mg/m2, ifosfamide 5 g/m2 with mesna 5 g/m2, biweekly with G-CSF 5 micrograms/kg (filgrastim), in terms of toxicity, clinic 10612219 Human
g-csf nasopharyngeal cancer We have studied the effects of timing of administration of G-CSF in 21 patients who had autologous stem cell transplantation for breast cancer, lymphoma or nasopharyngeal cancer. 10698469 Human
g-csf cancer of the testis The yield of CD34+ PBPC and colony-forming units-granulocyte-macrophage (CFU-GM) in leukapheresis products and the expression of the adhesion molecules CD11a, CD31, CD49d, CD49e, CD54, CD58, CD62L, c-kit (CD117), Thy-1 (CD90), CD33, CD38, and HLA-DR on CD 10791904 Human
granulocyte colony stimulating factor childhood acute myeloid leukemia OBJECTIVE: To evaluate the effect of recombinant human granulocyte colony stimulating factor (rhG-CSF) on accelerating neutrophil recovery and decrease fatal infections for childhood acute myeloid leukemia (AML). 11601256 Human
lenograstim metastatic pancreatic carcinoma Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) an 10027318 Human
g-csf inflammatory bowel disease Tissue accumulation of polymorphonuclear neutrophils (PMN) in Inflammatory Bowel disease (IBD) might be, in part, due to a delay in apoptotic processes associated with the effects of their specific growth factors and inflammatory cytokines.We addressed th 10029277 Human
g-csf blast crisis Twenty-one patients with advanced chronic myeloid leukemia (late chronic phase (n = 8), accelerated phase (n = 11) and blast crisis (n = 2)) were treated with idarubicin, cytarabine, and etoposide followed by G-CSF and subsequent collection of peripheral 10071133 Human
g-csf stage iv ovarian carcinoma PURPOSE: To evaluate the feasibility of administering topotecan in combination with paclitaxel and cisplatin without and with granulocyte colony-stimulating factor (G-CSF) support as first-line chemotherapy in women with incompletely resected stage III an 10071262 Human
filgrastim refractory cancer Phase I trial of paclitaxel, carboplatin, and topotecan with or without filgrastim (granulocyte-colony stimulating factor) in the treatment of patients with advanced, refractory cancer. 10091804 Human
filgrastim hairy-cell leukemia Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. 10194424 Human
granulocyte colony stimulating factor poorly differentiated thyroid carcinoma The secretion of cytokines and granulocyte colony stimulating factor by anaplastic and poorly differentiated thyroid carcinoma cell lines. 10216489 Human
g-csf thyroid carcinoma We examined the secretion of cytokines and G-CSF in four anaplastic (K119, IAA, KOA2 and MSA) and two poorly differentiated (SMP and CTP) thyroid carcinoma cell lines and compared them with the clinical courses of patients. 10216489 Human
g-csf poorly differentiated thyroid carcinomas CONCLUSION: Anaplastic and poorly differentiated thyroid carcinomas have the ability to secrete various cytokines and G-CSF, which may affect clinical symptoms of the patients at terminal stage. 10216489 Human
g-csf t-cell non-hodgkin lymphoma PROCEDURE: Seventeen children with acute lymphoblastic leukemia or T-cell non-Hodgkin lymphoma and treated on standard protocols were randomized to receive G-CSF following either the first or second intensification blocks of chemotherapy. 10219333 Human
g-csf transitional cell carcinoma G-CSF also has shown promise in stimulating neutrophil production in patients with transitional cell carcinoma, congenital agranulocytosis, and hairy-cell leukemia. 2690607 Human
g-csf chronic phase chronic myelogenous leukemia The monocyte, monocyte conditioned media (MoCM), giant cell tumor conditioned media (GCT) and a purified colony-stimulating factor (G-CSF) promote granulocyte-macrophage progenitors (CFU-GM) growth and differentiation along the neutrophil lineage and also 2457137 Human
g-csf refractory cancer First clinical studies performed with colony-stimulating factors have shown that neutropenia caused by drug-induced immunosuppression in patients with refractory cancer or autologous bone marrow transplantation was reversed using rh GM-CSF or rh G-CSF. 3071338 Human
g-csf diffuse large b-cell lymphomas Mitoxantrone, etoposide and prednisone (MEP)-based regimens using granulocyte colony-stimulating factor (G-CSF) were designed for relapsed and CHOP-resistant diffuse large B-cell lymphomas in a single institution, and the therapeutic effects and adverse r 11792410 Human
g-csf renal cancer As source of effector cells, whole blood from patients treated with G-CSF, GM-CSF or IL2/IFN-alpha was used in 51Cr- release assays using various renal cancer cell lines as tumor targets. 10365137 Human
g-csf pericardial mesothelioma However, this is the first case report of G-CSF production in a pericardial mesothelioma. 10374783 Human
g-csf wilms' tumor Constitutive expression of the Wilms' tumor gene WT1 inhibits the differentiation of myeloid progenitor cells but promotes their proliferation in response to granulocyte-colony stimulating factor (G-CSF). 10374864 Human
g-csf recurrent tumors G-CSF expression was significantly reduced in recurrent tumors more dedifferentiated than their primary counterparts. 10376937 Human
g-csf malignant mesothelioma High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. 10416012 Human
g-csf head and neck neoplasms We investigated the effect of granulocyte colony-stimulating factor (G-CSF) administration on radiotherapy (RT)-induced oral mucositis in 26 consecutive patients with head and neck neoplasms, stages III and IV, treated with hyperfractionated RT. 10435157 Human
g-csf diffuse malignant mesothelioma We report the rare case of a 61-year-old man with a diffuse malignant mesothelioma of mixed subtype which produced granulocyte colony-stimulating factor (G-CSF). 10440505 Human
g-csf mantle-cell lymphomas Twenty-six consecutive patients (10 follicular lymphomas, seven mantle cell lymphomas, seven B-CLL, two immunocytomas) were mobilized using chemotherapy plus G-CSF. 10455343 Human
g-csf follicular lymphomas Twenty-six consecutive patients (10 follicular lymphomas, seven mantle cell lymphomas, seven B-CLL, two immunocytomas) were mobilized using chemotherapy plus G-CSF. 10455343 Human
filgrastim stage-ii breast cancer PATIENTS AND METHODS: Women with stage II breast cancer and 10 or more involved nodes or four or more involved nodes and estrogen receptor-negative tumors and women with stage III disease received three cycles of epirubicin 200 mg/m2 and cyclophosphamide 10458221 Human
g-csf metastatic disease This trial evaluated the efficacy and tolerance of such a combination regimen with epirubicin and granulocyte colony-stimulating factor (G-CSF) in patients with metastatic disease. 10468299 Human
g-csf metastatic pancreatic adenocarcinoma We conclude that the combination of gemcitabine, epirubicin and G-CSF seems to be an effective palliative treatment with only moderate toxic effects in patients with metastatic pancreatic adenocarcinoma. 10468299 Human
g-csf esophageal small cell carcinoma Esophageal small cell carcinoma with ectopic production of parathyroid hormone-related protein (PTHrp), secretin, and granulocyte colony-stimulating factor (G-CSF). 10489911 Human
g-csf small cell carcinoma of the esophagus The present case is the first report of primary small cell carcinoma of the esophagus with ectopic production of PTHrp, secretin, and G-CSF. 10489911 Human
g-csf regional cancer Charts were reviewed of all patients > or = 65 years with newly diagnosed aggressive NHL referred to the Toronto-Sunnybrook Regional Cancer Centre (TSRCC) for initial management from 1990-1995 before routine use of G-CSF. 10512169 Human
g-csf malignant gliomas Seventeen patients less than or equal to 20 years of age with newly diagnosed (n = 10) or recurrent (n = 7) malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) were treated with cyclophosphamide in association with hematopoietic cytokin 9403013 Human
g-csf anaplastic astrocytoma Seventeen patients less than or equal to 20 years of age with newly diagnosed (n = 10) or recurrent (n = 7) malignant gliomas (anaplastic astrocytoma and glioblastoma multiforme) were treated with cyclophosphamide in association with hematopoietic cytokin 9403013 Human
g-csf t-cell leukemia In this study, we assessed the impact of r-metHu granulocyte colony-stimulating factor (G-CSF) on the period of neutropenia, number of days of hospitalization, and delays in subsequent administration of chemotherapy in a cohort of patients with T-cell leu 9469336 Human
filgrastim germ cell malignancy Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy. 9469362 Human
g-csf malignant germ-cell tumors PURPOSE: To determine the effect of r-metHu granulocyte colony-stimulating factor (G-CSF) on the proportion of patients with metastatic poor-prognosis malignant germ cell tumors who receive full dose-intensity combination chemotherapy. 9469362 Human
filgrastim malignant germ-cell tumors CONCLUSION: During combination chemotherapy in patients with malignant germ cell tumors, the routine use of filgrastim significantly improved the delivery of the planned treatment schedule without effect on failure-free or overall survival. 9469362 Human
g-csf large cell carcinoma of the lung Diffuse uptake of 201TI in the axial bone is reported in a patient with large cell carcinoma of the lung who showed leukocytosis and an increased concentration of granulocyte colony-stimulating factor (G-CSF) in plasma. 9476927 Human
g-csf metastatic disease These results demonstrate that G-CSF mediated FDG uptake in bone marrow is often indistinguishable from that caused by disseminated metastatic disease. 9481497 Human
filgrastim pediatric solid tumors CONCLUSION: The combination of topotecan and cyclophosphamide shows activity in a wide variety of pediatric solid tumors and can be given with acceptable hematopoietic toxicity with the use of filgrastim support. 9508177 Human
granulocyte colony stimulating factor gynecologic cancers Neutropenic patients suffering from gynecologic cancers treated with cancer chemotherapy were evaluated to investigate changes in levels of plasma alkaline phosphatase (ALP) during recombinant human granulocyte colony stimulating factor (rhG-CSF) administ 9517801 Human
filgrastim mantle-cell lymphoma A 49-year-old man with mantle cell lymphoma received 2.5 g/m2 of cyclophosphamide and 900 mg/m2 of etoposide followed by 10 microg/kg/day of Filgrastim for PBPC mobilization. 9603411 Human
g-csf esophageal tumor Immunohistochemical staining of the esophageal tumor was performed using monoclonal antibodies against granulocyte-colony stimulating factor (G-CSF), keratin, epithelial membrane antigen (EMA), and vimentin. 9610689 Human
g-csf metastatic disease Twenty-four patients with MBC and no previous chemotherapy for metastatic disease were treated with high-dose cyclophosphamide (5000 mg/m2), and etoposide (1000 mg/m2) (CyVP16), followed by granulocyte colony-stimulating factor (G-CSF). 9674853 Human
g-csf aplasia All 8 animals given G-CSF had severe aplasia and 7 died at day 8 (range, 5 to 10); 1 animal survived, with G-CSF being administered before TBI. 9680342 others
g-csf transitional cell carcinomas In this review, G-CSF and tumor cell growth, particularly of human transitional cell carcinomas of the bladder, are discussed, and autocrine growth of human solid tumors is also summarized. 9681250 Human
g-csf adult t-cell leukemia We evaluated the effect of granulocyte colony-stimulating factor (G-CSF) on the median survival of 17 patients with Adult T-cell leukemia (ATL). 9684938 Human
g-csf endometrial carcinomas METHODS: A total of 111 patients with ovarian, cervical, or endometrial carcinomas or benign ovarian or uterine tumors were enrolled on the study, and the levels of interleukin (IL)-2, IL-4, IL-6, IL-10, interferon (IFN)-gamma, granulocyte-colony stimulat 9708947 Human
g-csf intermediate-grade lymphoma The purpose of this study was to assess the safety and feasibility of using standard and escalated doses of cyclophosphamide with doxorubicin, vincristine and prednisone (CHOP) plus granulocyte colony stimulating factor (G-CSF) to treat elderly patients w 9711921 Human
granulocyte colony stimulating factor intermediate-grade lymphoma The purpose of this study was to assess the safety and feasibility of using standard and escalated doses of cyclophosphamide with doxorubicin, vincristine and prednisone (CHOP) plus granulocyte colony stimulating factor (G-CSF) to treat elderly patients w 9711921 Human
g-csf testicular germ cell tumour Peptide growth factors involved in the regulation of haematopoiesis (HPGF), for example granulocyte-colony-stimulating factor (G-CSF) and granulocyte/macrophage-colony-stimulating factor (GM-CSF), are of clinical importance in the treatment of testicular 9750020 Human
g-csf malignant mesothelioma High-dose ifosfamide with mesna and granuloctye-colony-stimulating factor (recombinant human G-CSF) in patients with unresectable malignant mesothelioma. 12872353 Human
g-csf secondary myelodysplastic syndrome We report a case of secondary myelodysplastic syndrome (MDS) with monosomy 7, which evolved from severe aplastic anemia (SAA) after long-term use of granulocyte colony-stimulating factor (G-CSF). 9803678 Human
filgrastim high-grade lymphoma We performed a prospective randomised placebo-controlled trial using topical oral r-metHuG-CSF (filgrastim) in high-grade lymphoma patients treated according to the B-NHL protocol, which contains high-dose methotrexate and causes severe oral mucositis (WH 9827976 Human
g-csf multiple myeloma Leukapheresis collections of mobilized peripheral blood mononuclear cells (PBMCs) were obtained from normal donors receiving granulocyte colony-stimulating factor (G-CSF) (for allogeneic PBSCT) and from intermediate grade non-Hodgkin's lymphoma or mu 9829733 Human
g-csf metastatic cancer A dose of 5 microg G-CSF kg(-1) day(-1) [recombinant human (rHu) G-CSF; filgrastim] or 250 microg GM-CSF m(-2) day(-1) (rHu GM-CSF; molgramostim) was administered subcutaneously once daily to 12 metastatic cancer patients being treated with different cyto 9829843 Human
filgrastim metastatic cancer A dose of 5 microg G-CSF kg(-1) day(-1) [recombinant human (rHu) G-CSF; filgrastim] or 250 microg GM-CSF m(-2) day(-1) (rHu GM-CSF; molgramostim) was administered subcutaneously once daily to 12 metastatic cancer patients being treated with different cyto 9829843 Human
g-csf placental-site trophoblastic tumor The use of dose-intensive, multi-agent chemotherapy, early intervention when metastatic disease is discovered, imaging techniques to define disease spread, surgery for localized disease and the use of growth factors, most notably granulocyte colony-stimul 9833615 Human
g-csf metastatic disease The use of dose-intensive, multi-agent chemotherapy, early intervention when metastatic disease is discovered, imaging techniques to define disease spread, surgery for localized disease and the use of growth factors, most notably granulocyte colony-stimul 9833615 Human
g-csf esophageal squamous-cell carcinomas Patients with head and neck cancers that produce a high concentration of granulocyte colony-stimulating factor (G-CSF) or patients with esophageal squamous cell carcinomas who have elevated serum interleukin-6 (IL-6) concentrations have been found previou 9833216 Human
filgrastim metastatic neuroblastoma An open-label, multicentre, randomised phase 2 study of recombinant human granulocyte colony-stimulating factor (filgrastim) as an adjunct to combination chemotherapy in paediatric patients with metastatic neuroblastoma. 9849455 Human
filgrastim metastatic neuroblastoma The objective of this randomised multicentre study was to assess the incidence, duration and severity of neutropenia when filgrastim is added to induction chemotherapy administered to patients with metastatic neuroblastoma. 9849455 Human
filgrastim metastatic neuroblastoma In this study, 59 patients with metastatic neuroblastoma were randomised to receive chemotherapy (control group, n = 28) or chemotherapy plus filgrastim (filgrastim group, n = 31). 9849455 Human
filgrastim metastatic neuroblastoma Filgrastim is a beneficial adjunct to combination induction chemotherapy used in the treatment of metastatic neuroblastoma. 9849455 Human
g-csf ewing sarcoma Reduced tumor load in peripheral blood after treatment with G-CSF and chemotherapy in children with tumors of the Ewing sarcoma family but not neuroblastoma. 14568910 Human
g-csf gastroesophageal cancer CONCLUSION: Our data suggest that the combination of docetaxel and cisplatin with or without G-CSF and/or erythropoietin has a promising therapeutic index in patients with advanced gastroesophageal cancer. 14657594 Human
g-csf follicular-center-cell lymphoma Neoplastic B cells from follicular center cell lymphoma patients, which are the counterparts of normal GC B lymphocytes, also released G-CSF spontaneously in culture. 8990100 Human
g-csf recurrent ovarian cancer Due to the inability to administer near relevant single-agent doses of both drugs in combination, as well as the requirement for G-CSF support, further evaluations of this regimen in women with refractory or recurrent ovarian cancer are necessary before i 8996140 Human
gcsf metastatic adenocarcinoma This brief report illustrates the presence of lipid-laden macrophages in proximity to metastatic adenocarcinoma cells within the bone marrow of a patient receiving taxol and GCSF therapy. 9028386 Human
g-csf melanoma Ectopic G-CSF expression in human melanoma lines marks a trans-dominant pathway of tumor progression. 9060833 Human
g-csf melanoma Evaluation of this revealed the cause to be massive myelopoiesis due to ectopic granulocyte/ colony-stimulating factor (G-CSF) production by the melanoma cells. 9060833 Human
g-csf melanoma Because of these observations linking G-CSF expression with metastasis of human melanoma, we decided to investigate the mechanism of this ectopic production. 9060833 Human
g-csf melanoma The suggestion of a trans-dominant mechanism was further supported by transfection studies with a human G-CSF promoter-CAT-reporter construct, which revealed 3- to 5-fold increased reporter activity in only those melanoma lines and hybrids expressing G-CS 9060833 Human
g-csf large-cell carcinoma Northern blot analysis revealed G-CSF gene expression in 14 of 84 surgical specimens (16.7%, 10/30 squamous cell carcinoma, 3/50 adenocarcinoma, 1/4 large cell carcinoma). 9066582 Human
g-csf adult t-cell leukaemia lymphoma Granulocyte-colony stimulating factor (G-CSF) is known to induce proliferation and differentiation of granulocyte progenitors, and is widely used to treat neutropenia induced by intensive chemotherapy for malignant lymphoma or adult T-cell leukaemia/lymph 9074411 Human
g-csf germ-cell cancer In the first, with germ cell cancer, six 12-liter leukaphereses yielded 1.8 x 10(6) CD34+ cells/kg after mobilization with cis-platinum, etoposide and ifosfamide (PEI) plus granulocyte colony-stimulating factor (G-CSF). 9088081 Human
g-csf large granular lymphocytic leukemia A 50-year-old man with large granular lymphocytic leukemia (CD3+, CD8+) complicated by severe pancytopenia and life-threatening infections refractory to therapy with prednisone, methotrexate, cyclosporine, and G-CSF is described. 9092691 Human
g-csf chronic phase cml G-CSF and GM-CSF were found to considerably decrease the rate of apoptosis in chronic phase CML neutrophils (p < 0.001 and p = 0.008 respectively) while IL-1beta did not show any antiapoptotic effect. 9130620 Human
g-csf relapsed chronic myelogenous leukemia In 7 children (5 with neuroblastoma IV, 1 with multifocal Ewing's sarcoma, and 1 with rhabdomyosarcoma IV), stem cells were mobilized by application of G-CSF at a dosage of 15-27.7 micrograms/kg body weight (median 16.25) subcutaneously following hig 9180913 Human
g-csf rhabdomyosarcoma In 7 children (5 with neuroblastoma IV, 1 with multifocal Ewing's sarcoma, and 1 with rhabdomyosarcoma IV), stem cells were mobilized by application of G-CSF at a dosage of 15-27.7 micrograms/kg body weight (median 16.25) subcutaneously following hig 9180913 Human
filgrastim breast and ovarian cancer Collection of peripheral blood stem cells following administration of paclitaxel, cyclophosphamide, and filgrastim in patients with breast and ovarian cancer. 9267668 Human
filgrastim breast and ovarian cancer PURPOSE: To determine the toxicities and efficacy of paclitaxel, cyclophosphamide (Cy), and recombinant human granulocyte-colony stimulating factor (filgrastim) administered for mobilization and collection of peripheral blood stem cells (PBSC) in patients 9267668 Human
filgrastim breast and ovarian cancer CONCLUSIONS: The combination of paclitaxel, Cy, and filgrastim can be administered with acceptable toxicity, allowing collection of adequate quantities of PBSC from the majority of patients with breast and ovarian cancer. 9267668 Human
g-csf synovial sarcoma We retrospectively analysed 62 leukaphereses performed on eleven patients with Ewing Tumors and one patient with Synovial Sarcoma, all after treatment with standardized chemotherapy (according to the EICESS protocol) and subsequent administration of G-CSF 9293449 Human
g-csf squamous-cell cancer In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support. 9311440 Human
g-csf recurrent breast cancer To evaluate the efficacy and toxicity of high-dose epirubicin (EPI) plus cyclophosphamide (CPA) therapy, a phase II study of EPI, 130 mg/m2, plus CPA, 1000 mg/m2, with G-CSF every 3 weeks was carried out for 51 advanced or recurrent breast cancer patients 9390210 Human
g-csf follicular lymphoma In patients with previously untreated advanced follicular lymphoma, trilineage hematopoietic engraftment was compared in two sequential trials of induction therapy (standard dose cyclophosphamide, doxorubicin, vincristine, prednisone [CHOP] without growth 9389719 Human
g-csf aids-related lymphoma We studied the effect of G-CSF on neutrophil increment and levels of soluble Fc gamma receptor type III in 15 patients with AIDS-related lymphoma (ARL) undergoing chemotherapy. 9401062 Human
filgrastim high-grade lymphomas Filgrastim increases leukocyte and neutrophil counts and dose intensity, if used with CEOP/IMVP-Dexa chemotherapy in high-grade lymphomas. 9402845 Human
g-csf b-cell lymphoma A trial with transgenic mice, evaluating the efficacy of these hFc gamma RI-directed bsAb in combination with G-CSF for treatment of IIA1.6 B cell lymphoma, is currently in progress. 9435865 Human
g-csf female breast carcinoma Hematologic effects of granulocyte colony-stimulating factor (G-CSF) and erythropoietin (EPO) combination after printing intensive chemotherapy in the treatment of female breast carcinoma are presented. 9473775 Human
g-csf pediatric solid tumors In this study, experience with the use of G-CSF (Neupogen, Roche) after 123 courses of highly myelosuppressive chemotherapy administered to 31 (20 female, 11 male) patients with pediatric solid tumors is reported. 10897813 Human
g-csf bone sarcomas BACKGROUND AND OBJECTIVES: We analyzed the correlations between pretreatment serum levels of 11 cytokines and soluble cytokine receptors (interleukin 6 (IL-6); interleukin 8 (IL-8); interleukin 10 (IL-10); vascular endothelial growth factor (VEGF); basic 14598359 Human
g-csf colon adenocarcinoma C-26 colon adenocarcinoma cells transduced with the granulocyte colony-stimulating factor (G-CSF) gene form large tumors when injected into sublethally irradiated mice. 8579110 Human
g-csf blast crisis Leukemic cells from the bone marrows of 26 patients with AML and CML in blast crisis were incubated with G-CSF, GM-CSF and IL-3 for 24 h prior to incubation with cytostatic drugs. 8599980 Human
g-csf jcml In contrast, stem cell factor (SCF), granulocyte-macrophage colony-stimulating factor (GM-CSF), and interleukin-3 (IL-3), as well as G-CSF, when tested individually, generated significant numbers of GM colonies in some JCML patients. 8641332 Human
g-csf brainstem glioma The authors report a child with brainstem glioma who received repeated cycles of multiagent chemotherapy with G- or GM-CSF support. 8614371 Human
g-csf human hepatoma In human hepatoma HepG2 and Hep3B cells, IL-1 beta induced production of the granulocyte colony-stimulating factor (G-CSF) in a dose-dependent manner. 8639772 Human
g-csf cyst We investigated the expression of granulocyte colony-stimulating factor (G-CSF), G-CSF mRNA, and G-CSF receptor mRNA in astrocytoma cell lines, G-CSF in astrocytoma cyst fluid, and the effect of recombinant G-CSF on the proliferation of astrocytoma cells 8699223 Human
g-csf cyst We also analyzed the presence of G-CSF by ELISA in five astrocytoma cyst fluids. 8699223 Human
g-csf liver cancer 'Sho-saiko-to' (TJ-9) is a Japanese herbal medicine that is commonly administered to patients with chronic viral liver disease in order to improve their overall physical condition and to prevent the development of liver cancer, The present in vi 8672758 Human
g-csf transitional-cell bladder carcinoma A 63-year-old man with a progressive, grade 3 transitional cell bladder carcinoma, showed marked leukocytosis (maximum 181,800/mm3) and an elevated serum G-CSF to 131.7 pg/mL. 8689512 Human
g-csf recurrent tumor Immunohistochemical examination with monoclonal antibody specific for G-CSF revealed positive staining in the local recurrent tumor. 8689512 Human
g-csf adult t-cell leukemia lymphoma (atll) SUMMARY: An intensive combination chemotherapy regimen supported by granulocyte colony-stimulating factor (G-CSF) was evaluated in adult T-cell leukemia/lymphoma (ATLL) patients in a multiinstitutional, cooperative study. 8680890 Human
g-csf blast crisis Peripheral blood and bone marrow changes after treatment with ATRA and G-CSF in AML, APL and blast crisis following Vaquez's disease. 8767533 Human
g-csf cancer of the testis In this single center study, we compared the effectiveness of two different doses of G-CSF on the mobilization of peripheral blood stem cells in patients with Hodgkin's disease, non-Hodgkin's lymphoma, and cancer of the testis. 8733686 Human
g-csf b-cell lymphoma A small fraction of fresh B blasts from six patients with B-cell lymphoma and leukaemia displayed G-CSF binding by two-colour immunofluorescence staining. 8759883 Human
g-csf recurrent endometrial cancer METHODS: Thirty patients with advanced or recurrent endometrial cancer with measurable disease not previously treated with chemotherapy were treated with paclitaxel, 250 mg/m2, over 24 hr with G-CSF, 5 mcg/kg/day, from Days 2 to 12. 8751561 Human
granulocyte colony stimulating factor extensive small-cell lung cancer The limits of chemotherapy dose intensification using granulocyte colony stimulating factor alone in extensive small cell lung cancer. 8794414 Human
g-csf childhood leukemias Heterogeneous effects of G-CSF and GM-CSF on cell growth and ara-C cytotoxicity in childhood leukemias which express myeloid markers. 8819077 Human
g-csf childhood leukemia These results indicate the heterogeneous effects of G-CSF and GM-CSF on cell growth and ara-C sensitivity in childhood leukemia cells. 8819077 Human
g-csf bone metastases On long TE IR-TSE, the changes are visible during G-CSF treatment and can lead to misinterpretations in the response evaluation of bone metastases to therapy. 14510752 Human
filgrastim germ-cell cancer PATIENTS AND METHODS: Twenty male patients with a histologic diagnosis of advanced-stage germ-cell cancer, previously untreated with chemotherapy, received the following: etoposide 75 mg/m2 i.v. days 1-5; ifosfamide (with mesna uroprotection) 1.2 g/m2 i.v 8823477 Human
g-csf chronic neutrophilic leukemia Serum G-CSF levels in primary myelofibrosis and chronic neutrophilic leukemia as estimated by the highly sensitive chemiluminescence enzyme immunoassay (CLEIA). 8882966 Human
g-csf primary myelofibrosis Serum G-CSF levels in primary myelofibrosis and chronic neutrophilic leukemia as estimated by the highly sensitive chemiluminescence enzyme immunoassay (CLEIA). 8882966 Human
g-csf secondary myelofibrosis In this study, we clarify the difference in serum G-CSF levels between patients with primary myelofibrosis (PMF, myelofibrosis with myeloid metaplasia; MMM) and those with secondary myelofibrosis caused by several hematological disorders, using the same h 8882966 Human
g-csf myelofibrosis In this study, we clarify the difference in serum G-CSF levels between patients with primary myelofibrosis (PMF, myelofibrosis with myeloid metaplasia; MMM) and those with secondary myelofibrosis caused by several hematological disorders, using the same h 8882966 Human
g-csf myeloid metaplasia In this study, we clarify the difference in serum G-CSF levels between patients with primary myelofibrosis (PMF, myelofibrosis with myeloid metaplasia; MMM) and those with secondary myelofibrosis caused by several hematological disorders, using the same h 8882966 Human
g-csf primary myelofibrosis In this study, we clarify the difference in serum G-CSF levels between patients with primary myelofibrosis (PMF, myelofibrosis with myeloid metaplasia; MMM) and those with secondary myelofibrosis caused by several hematological disorders, using the same h 8882966 Human
g-csf extensive small-cell lung cancer Phase I study of chemotherapy with carboplatin, epirubicin, and escalating dose of VP-16 with G-CSF support in extensive small cell lung cancer. 8931678 Human
g-csf extensive small-cell lung cancer In attempt to develop a new chemotherapeutic regimen including carboplatin (CBDCA), epirubicin (EPI), and VP-16 in extensive small cell lung cancer, with a higher dose intensity compared with previous experience of our group, we determined the maximum tol 8931678 Human
g-csf stage iv neuroblastoma G-CSF primed peripheral blood progenitor cells (PBPC) autotransplantation in stage IV Neuroblastoma and poor risk solid tumors. 8932826 Human
g-csf thyroid cancer We report here a case of a thyroid cancer producing both granulocyte colony-stimulating factor (G-CSF) and granulocyte-macrophage colony-stimulating factor (GM-CSF). 8933194 Human
g-csf thyroid tumor Furthermore, the G-CSF concentrations in thyroid tumor tissue and metastatic lesions in the lung and skin examined at autopsy also were extremely high. 8933194 Human
g-csf chronic neutrophilic leukaemia In order to study the pathogenesis of plasma cell dyscrasias with associated clinical features of chronic neutrophilic leukaemia, the concentration of granulocyte-colony stimulating factor (G-CSF) was measured in a patient, a 73 year old man, who underwen 8943758 Human
g-csf choriocarcinoma Human endometrial expression of granulocyte colony-stimulating factor (G-CSF) and its receptor, stimulation of endometrial G-CSF production by interleukin-1 beta, and G-CSF inhibition of choriocarcinoma cell proliferation. 8955505 Human
g-csf choriocarcinoma G-CSF effects on proliferation of three choriocarcinoma cell lines were determined. 8955505 Human
g-csf choriocarcinoma G-CSF inhibited proliferation of two choriocarcinoma cell lines. 8955505 Human
g-csf malignant ascites The aim of this study was to elucidate the effect of intraperitoneal (i.p.) instillations of granulocyte-colony-stimulating factor (G-CSF) and/or interleukin-2 (IL-2) on ascites formation and the survival time of nude mice with malignant ascites, produced 9024501 Human
g-csf large-cell carcinoma In patients with large cell carcinoma, endogenous G-CSF, M-CSF, and IL-6 levels were significantly higher than those in patients with carcinomas of other cell types (P < 0.05). 9816203 Human
g-csf non-small cell lung cancer Univariate analysis showed that survival of 159 non-small cell lung cancer patients with high (more than cutoff level) G-CSF, M-CSF, and IL-6 levels was significantly poorer than that of patients with low levels (Wilcoxon's test, P = 0.018, P < 0. 00 9816203 Human
g-csf squamous-cell cancer Paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated at this dose schedule with G-CSF support. 9816298 Human
granulocyte colony stimulating factor choriocarcinoma The effect of human granulocyte colony stimulating factor (hG-CSF) was investigated on the proliferation of choriocarcinoma cells in vitro. 7531835 Human
g-csf acute myelomonocytic leukemia Leukemic nodules at the site of G-CSF injection in acute myelomonocytic leukemia. 7532140 Human
g-csf acute myelomonocytic leukemia Bone marrow aspirate and flow cytometry study results were consistent with acute myelomonocytic leukemia but were normal after G-CSF was discontinued for 4 days. 7536347 Human
g-csf malignant mesothelioma We present the case of a male patient, aged 45 yrs, with malignant mesothelioma producing granulocyte colony-stimulating factor (G-CSF). 7538085 Human
g-csf anaplastic thyroid carcinoma Anaplastic thyroid carcinoma producing the granulocyte colony stimulating factor (G-CSF): report of a case. 7539648 Human
granulocyte colony stimulating factor anaplastic thyroid carcinoma Anaplastic thyroid carcinoma producing the granulocyte colony stimulating factor (G-CSF): report of a case. 7539648 Human
g-csf anaplastic thyroid carcinoma We report herein the unusual case of a 60-year-old woman with an anaplastic thyroid carcinoma which produced granulocyte colony stimulating factor (G-CSF). 7539648 Human
granulocyte colony stimulating factor anaplastic thyroid carcinoma We report herein the unusual case of a 60-year-old woman with an anaplastic thyroid carcinoma which produced granulocyte colony stimulating factor (G-CSF). 7539648 Human
g-csf murine leukemia Their proliferation was compared with that of a G-CSF dependent murine leukemia cell line (NFS-60). 7540401 Human
g-csf adult acute lymphoblastic leukemia This prospective multicenter study examined whether simultaneous administration of granulocyte colony-stimulating factor (G-CSF; Filgrastim) and induction chemotherapy for adult acute lymphoblastic leukemia (ALL) could prevent treatment-related neutropeni 7541660 Human
g-csf polycythemia vera The suppressive effect by TGF-beta 1 was increased for growth with GM-CSF, IL-3, and SCF, and growth with G-CSF was unaffected in hematologic malignancies, TGF-beta 1 suppression for growth with G-CSF was increased for essential thrombocythemia (ET) and p 7543418 Human
g-csf hematologic malignancies The suppressive effect by TGF-beta 1 was increased for growth with GM-CSF, IL-3, and SCF, and growth with G-CSF was unaffected in hematologic malignancies, TGF-beta 1 suppression for growth with G-CSF was increased for essential thrombocythemia (ET) and p 7543418 NA
g-csf murine erythroleukemia Transfection of murine 32D and murine erythroleukemia (MEL) cell lines with DR1-myb caused inhibition of cellular differentiation induced by granulocyte colony-stimulating factor (G-CSF) and dimethyl sulfoxide (DMSO), respectively. 7579444 Mouse
g-csf thymic cancer A study was conducted to evaluate the impact of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) with granulocyte colony-stimulating factor (G-CSF) on advanced thymoma or thymic cancer. 7474409 Human
g-csf thymic cancer Between August 1989 and December 1994, 14 patients with invasive, metastatic or recurrent thymoma or thymic cancer were treated with cisplatin (80 mg/m2, on day 1), doxorubicin (45 mg/m2, on day 1), cyclophosphamide (800 mg/m2, on day 1) and etoposide (80 7474409 Human
g-csf thymic cancer In conclusion, PACE with G-CSF frequently produces objective remissions in patients with advanced thymoma or thymic cancer. 7474409 Human
g-csf lymphocytic leukemia The mean (+/-SD) Mg content of MBCs isolated from patients diagnosed with lymphocytic leukemia, myelocytic leukemia, or infection; from patients treated with granulocyte colony-stimulating factor (G-CSF); and from healthy volunteers (control group) was 2. 7497618 Human
g-csf lymphocytic leukemia The mean Mg concentration of granulocytes obtained from lymphocytic leukemia, myelocytic leukemia, infection, and G-CSF patients and from the control group was 3.2 (+/-0.9), 3.4 (+/-0.5), 3.8 (+/-0.6), 4.5 (+/-0.6), and 4.6 (+/-0.6) fmol/cell, respectivel 7497618 Human
g-csf myeloid leukaemia While the other murine CSFs (granulocyte-macrophage (GM)-CSF, macrophage (M)-CSF and multi-CSF) show little or no differentiation-inducing activity on murine myelomonocytic leukaemia cell lines, G-CSF (or MGI-2(6)) is able to induce the production of term 2986009 Mouse
g-csf myelomonocytic leukaemia While the other murine CSFs (granulocyte-macrophage (GM)-CSF, macrophage (M)-CSF and multi-CSF) show little or no differentiation-inducing activity on murine myelomonocytic leukaemia cell lines, G-CSF (or MGI-2(6)) is able to induce the production of term 2986009 Human
g-csf human myeloid leukaemia It is important to identify the human analogue of murine G-CSF so that its effectiveness on human myeloid leukaemia cells can be assessed. 2986009 Human
g-csf tumor Iodinated G-CSF bound specifically to WEHI-3B cells, J774 macrophage tumor cells, and normal murine bone marrow cells but not to a variety of other tumor cell lines or murine thymocytes. 6610179 Mouse
g-csf bladder carcinoma The human bladder carcinoma cell line 5637 produces hematopoietic growth factors [granulocyte and granulocyte/macrophage colony-stimulating factors (G-CSF and GM-CSF)] and hemopoietin 1, which synergizes with CSFs to stimulate colony formation by primitiv 3499607 Human
pluripoietin bladder carcinoma Pluripoietin alpha: a second human hematopoietic colony-stimulating factor produced by the human bladder carcinoma cell line 5637. 3458209 Human
g-csf giant-cell tumor In order to obtain more insight into the nature of the abnormal in vitro colony formation in myelodysplastic syndromes (MDS), we investigated the kinetics of the colony formation of 23 MDS cases in response to recombinant human interleukin-3 (IL-3), Granu 1694940 Human
filgrastim recurrent ovarian cancer PURPOSE: To determine if increasing the dose of paclitaxel increases the probability of clinical response, progression-free survival, or overall survival in women who have persistent or recurrent ovarian cancer, and whether doubling the dose of prophylact 12807937 Human
g-csf low-grade lymphoma In a phase I/II clinical trial, we investigated the safety and efficacy of the combination of rituximab and G-CSF (5 microg/kg/day, administered for 3 days, starting 2 days before each infusion) in 26 relapsed low-grade lymphoma patients. 12886256 Human
granulocyte colony stimulating factor blastic phase cml We evaluated the effects of recombinant human interleukin-3 (rh-IL-3), granulocyte-macrophage colony stimulating factor (rhGM-CSF) and granulocyte colony stimulating factor (rhG-CSF) alone and in combination on AML (N = 11) and blastic phase CML (N = 3) s 2243506 Human
g-csf thyroid cancer The expression of granulocyte colony-stimulating factor (G-CSF) mRNA was studied in human non-hematopoietic tumors, including 18 cases of lung cancers 10 cases of stomach cancers, three cases of glioblastomas, and one case each of breast phyllode sarcoma, 1701653 Human
g-csf b-acute lymphoblastic leukemia We have tested a panel of recombinant hematopoietic growth factors (HGF) including the interleukins (IL) 1, 2, 3, 4, and 6 and the colony stimulating factors GM-CSF, G-CSF, M-CSF for their ability to induce proliferation of precursor B acute lymphoblastic 2497281 Human
g-csf malignant mesothelioma However, in contrast to normal mesothelial cells, two of four malignant mesothelioma cell lines also autonomously expressed G-CSF and GM-CSF transcripts without TNF, EGF, or LPS stimulation. 2787682 Human
g-csf human malignant mesothelioma These data indicate that (a) normal human mesothelial cells spontaneously express detectable levels of M-CSF mRNA in culture; (b) EGF is an essential cofactor for optimal induction of G-CSF and GM-CSF expression; (c) exposure of normal mesothelial cells t 2787682 Human
g-csf large cell carcinoma of the lung Establishment of a G-CSF and GM-CSF producing cell line from human large cell carcinoma of the lung. 2477274 Human
g-csf breast and ovarian cancer Granulocyte colony stimulating factor (G-CSF) was given to 17 patients with advanced breast and ovarian cancer in order to increase the intensity and effectiveness of chemotherapy. 2478178 Human
granulocyte colony stimulating factor breast and ovarian cancer Granulocyte colony stimulating factor (G-CSF) was given to 17 patients with advanced breast and ovarian cancer in order to increase the intensity and effectiveness of chemotherapy. 2478178 Human
g-csf ascites tumor In contrast to this ascites tumor model, solid tumors induced by intradermal transplantation of BAMC-1 tumor cells were resistant to the combined treatments with OK-432 and G-CSF, dying within 60 days. 8964656 Human
g-csf extensive small-cell lung cancer Phase II study of intensive CEV (carboplatin, epirubicin and VP-16) plus G-CSF (granulocyte-colony stimulating factor) in extensive small cell lung cancer. 8652288 Human
g-csf acute leukemia in remission We concluded that, the production of G-CSF and GM-CSF as a response to infection was deficient in the patients with acute leukemia in remission, probably due to the maintenance and reinforcement chemotherapy. 8721901 Human
g-csf oral cancer Simultaneous production of G- and M-CSF by an oral cancer cell line and the synergistic effects on associated leucocytosis. 8704650 Human
g-csf oral cancer These results indicate that not only G-CSF but also M-CSF, both of which could be produced by TSU cells, are involved in causing leucocytosis; the results suggest that the synergistic production of G- and M-CSF could play an important role in the leucocyt 8704650 Human
g-csf recurrent ovarian carcinoma PURPOSE: Our purpose was to conduct a phase II clinical trial investigating the response of patients with advanced recurrent ovarian carcinoma to high-dose paclitaxel combined with granulocyte colony-stimulating factor (G-CSF). 7505830 Human
filgrastim acute promyelocytic leukaemia Filgrastim combined with tretinoin in acute promyelocytic leukaemia. 7510817 Human
g-csf astrocytoma Using the murine monoclonal anti-G-CSF TM 82/60 antibody, we found high G-CSF expression in astrocytoma WHO grades I and II and reactive brain tissue, low expression in astrocytoma WHO grade III, and none in glioblastoma, oligodendroglioma WHO grades II a 7513314 Mouse
g-csf oligodendroglioma Using the murine monoclonal anti-G-CSF TM 82/60 antibody, we found high G-CSF expression in astrocytoma WHO grades I and II and reactive brain tissue, low expression in astrocytoma WHO grade III, and none in glioblastoma, oligodendroglioma WHO grades II a 7513314 Mouse
g-csf transitional cell carcinoma A patient presented with grade 3 transitional cell carcinoma of the bladder showing a marked increase in granulocyte colony-stimulating factor (G-CSF). 7513915 Human
g-csf metastatic melanoma Dose escalation of dacarbazine combined with interferon alpha-2a, G-CSF and ondansetron in patients with metastatic melanoma. 7520681 Human
g-csf metastatic melanoma To define the activity of an individually escalated dacarbazine (DTIC) dose combined with interferon-alpha-2a (IFN), granulocyte-colony stimulating-factor (G-CSF) and ondansetron, 20 patients (pts) with metastatic melanoma were treated with DTIC, ondanset 7520681 Human
g-csf follicular-center-cell lymphoma Malignant B cells purified from the invaded lymph nodes of three patients with follicular center cell lymphoma and three Burkitt lymphoma cell lines, which had an immunophenotype identical with that of normal GC B cells, spontaneously produced G-CSF in vi 7522243 Human
g-csf burkitt lymphoma Malignant B cells purified from the invaded lymph nodes of three patients with follicular center cell lymphoma and three Burkitt lymphoma cell lines, which had an immunophenotype identical with that of normal GC B cells, spontaneously produced G-CSF in vi 7522243 Human
g-csf bone metastases METHODS: We performed 74 bone scans on 21 females with breast cancer and bone metastases entering a Phase II trial of Taxol chemotherapy with granulocyte colony stimulating factor (G-CSF). 7525900 Human
granulocyte colony stimulating factor bone metastases METHODS: We performed 74 bone scans on 21 females with breast cancer and bone metastases entering a Phase II trial of Taxol chemotherapy with granulocyte colony stimulating factor (G-CSF). 7525900 Human
lenograstim urothelial cancer Studies in advanced breast cancer, small cell lung cancer (SCLC), urothelial cancer and sarcoma indicate that recombinant human granulocyte colony stimulating factor (rHuG-CSF) (lenograstim) facilitates modest dose intensification (20-30%), but at high in 7535070 Human
granulocyte colony stimulating factor advanced urothelial cancer Schedule-intensified M-VAC chemotherapy for advanced urothelial cancer with recombinant human granulocyte colony stimulating factor (rhG-CSF). 7543010 Human
g-csf advanced ovarian cancer We investigated the serum concentrations of a variety of cytokines [granulocyte-macrophage-colony-stimulating factor (GM-CSF), granulocyte colony stimulating factor (G-CSF), interleukin (IL) 1 alpha, IL-3, IL-6, IL-8, erythropoietin, tumor necrosis factor 7680283 Human
g-csf squamous cell carcinoma of the head and neck High-dose mitomycin-C plus etoposide with G-CSF support may be useful for the treatment of patients with inoperable squamous cell carcinoma of the head and neck. 7683568 Human
granulocyte colony stimulating factor adenocarcinoma of the ovary The absence of cumulative bone marrow toxicity in patients with recurrent adenocarcinoma of the ovary receiving dose-intense taxol and granulocyte colony stimulating factor. 7683933 Human
g-csf adenocarcinoma of the ovary Forty-eight patients with recurrent adenocarcinoma of the ovary were treated with taxol and granulocyte colony stimulating factor (G-CSF), with a target taxol dose intensity of 250 mg/m2 every 3 weeks (83.3 mg/m2/week). 7683933 Human
granulocyte colony stimulating factor adenocarcinoma of the ovary Forty-eight patients with recurrent adenocarcinoma of the ovary were treated with taxol and granulocyte colony stimulating factor (G-CSF), with a target taxol dose intensity of 250 mg/m2 every 3 weeks (83.3 mg/m2/week). 7683933 Human
filgrastim myelodysplasia Preliminary results of treatment with filgrastim for relapse of leukemia and myelodysplasia after allogeneic bone marrow transplantation. 7688862 Human
filgrastim myelodysplastic syndrome METHODS. Seven female patients with leukemia (one with chronic myelogenous leukemia, five with acute myelogenous leukemia, and one with a myelodysplastic syndrome that transformed into acute myelogenous leukemia) whose disease relapsed within 360 days aft 7688862 Human
filgrastim chronic myelogenous leukemia METHODS. Seven female patients with leukemia (one with chronic myelogenous leukemia, five with acute myelogenous leukemia, and one with a myelodysplastic syndrome that transformed into acute myelogenous leukemia) whose disease relapsed within 360 days aft 7688862 Human
g-csf myelofibrosis Culture for 72 h with G-CSF or GM-CSF disclosed a minor abnormal clone which was undetected in 24 and 48 h cultures in a patient with myelofibrosis with myeloid metaplasia. 7690442 Human
g-csf myeloid metaplasia Culture for 72 h with G-CSF or GM-CSF disclosed a minor abnormal clone which was undetected in 24 and 48 h cultures in a patient with myelofibrosis with myeloid metaplasia. 7690442 Human
g-csf radiation-induced leukemia In the mice with radiation-induced leukemia, those receiving G-CSF had a mean survival time of 357 days, whereas those not receiving the factor survived for 349 days. 7691250 Mouse
g-csf transitional cell carcinoma of the renal pelvis In contrast, high levels of GM-CSF (132 pg ml-1), but not G-CSF or IL-3, were found in a patient with a transitional cell carcinoma of the renal pelvis and increased leukocytosis correlating with the tumour burden. 7691980 Human
filgrastim metastatic breast cancer Administration of human recombinant granulocyte colony-stimulating factor (filgrastim) accelerates granulocyte recovery following high-dose chemotherapy and autologous marrow transplantation with 4-hydroperoxycyclophosphamide-purged marrow in women with m 7693341 Human
g-csf pulmonary kaposi's sarcoma Chemotherapy for patients with pulmonary Kaposi's sarcoma: benefit of filgrastim (G-CSF) in supporting dose administration. 7694375 Human
filgrastim pulmonary kaposi's sarcoma Chemotherapy for patients with pulmonary Kaposi's sarcoma: benefit of filgrastim (G-CSF) in supporting dose administration. 7694375 Human
g-csf squamous cell lung cancer This is a case report of an 82-year-old man with squamous cell lung cancer which produced G-CSF. 7694692 Human
g-csf head and neck carcinomas Detectable levels of G-CSF by enzyme-linked immunosorbent assay (ELISA) were found in sera of 4 out of 15 patients with head and neck carcinomas. 7507344 Human
g-csf t-cell lymphoma BEAM regimen and G-CSF in HTLV-I-associated T-cell lymphoma. 1370235 Human
g-csf mesothelioma Analysis of conditioned media by ELISA revealed that all mesothelioma cell lines constitutively produced IL-6, while the MeT5A normal mesothelial cells did not; in addition, GM-CSF and G-CSF were detected in the supernatant of the ZL34 cell line. 1373705 Human
g-csf mesothelioma The mitogenic effect of the hematopoietic growth factors detected in mesothelioma culture supernatants was tested on mesothelioma cells and on MeT5A normal mesothelial cells: IL-6, GM-CSF and G-CSF did not stimulate any DNA synthesis. 1373705 Human
g-csf choriocarcinoma No G-CSF, measured as bioactivity or as mRNA, was detectable in choriocarcinoma cell lines. 1374054 Human
g-csf ki-1 lymphoma Ki-1 lymphoma producing G-CSF. 1374634 Human
g-csf murine adenocarcinoma Granulocyte colony-stimulating factor (G-CSF) gene transduction in murine adenocarcinoma drives neutrophil-mediated tumor inhibition in vivo. 1376745 Mouse
g-csf mixed tumor The suppression of tumorigenicity by G-CSF was limited to the G-CSF-producing cells and was not transferred to nonproducing C-26 cells in a mixed tumor transplantation assay. 1376745 Human
g-csf murine leukemia We demonstrate that, like LIF, IL-6 and G-CSF, OSM can induce the differentiation of the myeloblastic M1 murine leukemia cells into macrophage-like cells. 1380037 Mouse
g-csf m1 myeloid leukemia In the M1 myeloid leukemia, this induction of apoptosis was inhibited by granulocyte colony-stimulating factor (G-CSF) or interleukin-6 (IL-6) and to a lesser extent by IL-1 alpha. 1382703 Human
g-csf m1 leukemia As with TGF-beta 1, apoptosis induced by these cytotoxic compounds was inhibited by GM-CSF (7-M12 leukemia) and by G-CSF or IL-6 (M1 leukemia). 1382703 Human
g-csf malignant thymoma Increased serum G-CSF values ranging from 70 to 374 pg/ml were noted in 7 of 15 lung cancer cases, a case of malignant thymoma and a blastic crisis of chronic myelogenous leukemia. 1280490 Human
g-csf testicular cancer Alkaline phosphatase and lactate dehydrogenase changes during leucocytosis induced by G-CSF in testicular cancer. 1281904 Human
g-csf childhood acute lymphoblastic leukemia PURPOSE: In a previous randomized study, the authors reported that granulocyte colony-stimulating factor (G-CSF) increased the chemotherapy dose-intensity delivered during the consolidation therapy of high-risk childhood acute lymphoblastic leukemia (ALL) 12794521 Human
g-csf murine leukemia When stimulated in vitro with bacterial lipopolysaccharides (LPS), PBMC of those SCN patients produced G-CSF activity, as judged by proliferation induction of the murine leukemia cell line, NFS-60. 1705835 Mouse
g-csf colon adenocarcinoma We have investigated the effect of granulocyte colony-stimulating factor (G-CSF) delivery at the site of tumor growth by transducing, via retroviral vector, the human (hu) G-CSF gene into the colon adenocarcinoma C-26 and assaying the ability of transduce 1706752 Human
g-csf colon carcinoma A similar growth-enhancing effect of G-CSF was observed in models employing Meth 1 fibrosarcoma, colon carcinoma 26, and L1210 leukemia, although not all the effects were statistically significant. 1710615 Human
g-csf small-cell lung cancer METHODS. Patients with small-cell lung cancer were enrolled in a multicenter, randomized, double-blind, placebo-controlled trial of recombinant methionyl G-CSF to study the incidence of infection as manifested by fever with neutropenia (absolute neutrophi 1711156 Human
g-csf small-cell cancer The use of G-CSF as an adjunct to chemotherapy in patients with small-cell cancer of the lung was well tolerated and led to reductions in the incidence of fever with neutropenia and culture-confirmed infections; in the incidence, duration, and severity of 1711156 Human
filgrastim endometrial carcinoma Phase III trial of doxorubicin plus cisplatin with or without paclitaxel plus filgrastim in advanced endometrial carcinoma: a Gynecologic Oncology Group Study. 15169803 Human
g-csf jcml Therefore, we performed clonal CFU-GM assays, which more specifically reflect cytokine effects on CFU-GM, using JCML peripheral blood mononuclear cells (PBMNC) and neutralizing antibodies against GM-CSF, granulocyte colony-stimulating factor (G-CSF), macr 1915702 Human
g-csf jcml Monocytes from only a minority of JCML patients produced higher than normal quantities of GM-CSF, G-CSF, IL-1 beta, IL-6, and/or TNF alpha, but no obvious pattern could be discerned. 1915702 Human
g-csf neurofibromatosis Neurofibromatosis and increased risk of leukaemia--is the G-CSF gene involved? 1723132 Human
g-csf adult acute myeloid leukemia Granulocytic colony-stimulating factors (G-CSF and GM-CSF) in the treatment of adult acute myeloid leukemia. 1726333 Human
g-csf embryonal carcinoma Using a combination system of Transcription and PCR, we examined gene expression of TNF-alpha, TNF-beta and other cytokines (IL-1, G-CSF, IL-3 and IFN-gamma) in embryonal carcinoma cell lines (PCC3, PCC4, ECA2 and F9) and trophoblast cell line (PL/B6). 1842048 Human
g-csf myeloid hyperplasia The bone marrow (BM) at 12 hours is depleted of mature neutrophils and shows a left-shifted myeloid hyperplasia, consistent with the neutrophil-releasing and myeloproliferative activities of both IL-3 and G-CSF individually. 1688501 Human
g-csf myeloid hyperplasia The BM at 24 hours shows a replenished reserve of mature neutrophils and a synergistic left-shifted myeloid hyperplasia as compared with IL-3 and G-CSF alone. 1688501 Human
g-csf myeloid hyperplasia The BM after a week's administration of IL-3 plus G-CSF shows a generalized myeloid hyperplasia with a synergistic increase in mature neutrophils as compared with IL-3 or G-CSF alone. 1688501 Human
g-csf myeloid hyperplasia Daily injection of IL-3 plus G-CSF induced a significant decrease in erythroid, lymphoid, and eosinophilic marrow precursors, possibly owing to a myelophthisic effect of the myeloid hyperplasia and despite the fact that IL-3 alone induced a significant er 1688501 Human
g-csf mds The suppressive effect by TGF-beta 1 was increased for growth with GM-CSF, IL-3, and SCF, and growth with G-CSF was unaffected in hematologic malignancies, TGF-beta 1 suppression for growth with G-CSF was increased for essential thrombocythemia (ET) and p 7543418 NA
g-csf granular lymphocyte leukaemia Agranulocytosis associated with granular lymphocyte leukaemia: improvement of peripheral blood granulocyte count with human recombinant granulocyte colony-stimulating factor (G-CSF) 1690024 Human
g-csf other tumor Iodinated G-CSF bound specifically to WEHI-3B cells, J774 macrophage tumor cells, and normal murine bone marrow cells but not to a variety of other tumor cell lines or murine thymocytes. 6610179 Mouse
g-csf advanced cancer Bacterially synthesised human granulocyte colony-stimulating factor (G-CSF) was administered to patients with advanced cancer. 2467651 Human
g-csf lymphoid neoplasms Preliminary evidence suggests that G-CSF may also have a therapeutic role in indolent lymphoid neoplasms complicated by neutropenia. 2471274 Human
g-csf medulloblastoma In this study we investigated the ability of medulloblastoma cells, representing malignant embryonal neuroectodermal cells, to produce G-CSF. 1697636 Human
g-csf medulloblastoma Biological active and immunological detectable G-CSF was secreted by the medulloblastoma cell line DAOY and by one of the explanted tumor biopsies. 1697636 Human
g-csf medulloblastoma We conclude that in addition to previously described sources of G-CSF, neuroectodermally derived medulloblastoma cells are also able to produce G-CSF constitutively. 1697636 Human
g-csf cmml In CML and in chronic myelo-monocytic leukemia (CMML) PMNs, granulocyte colony-stimulating factor (G-CSF) specifically accumulates LAP mRNA without showing a substantial increase in the rate of transcription of the LAP gene. 1702329 Human
g-csf childhood acute megakaryoblastic leukemia [Induction of complete remission in a case of drug-resistant childhood acute megakaryoblastic leukemia by combination of G-CSF and chemotherapy] In a 4-year-old girl having acute megakaryoblastic leukemia, recombinant human granulocyte colony-stimulating 1374487 Human
g-csf large-cell carcinoma [Granulocyte colony-stimulating factor producing lung large cell carcinoma with sarcomatous transformation] We report a case of granulocyte colony-stimulating factor (G-CSF) producing lung large cell carcinoma with sarcomatous transformation. 1279257 Human
g-csf middle ear carcinoma [A case of middle ear carcinoma with high plasma G-CSF level] Malignant tumors sometimes yield a variety of paraneoplastic syndrome. 7682610 Human
g-csf transitional carcinoma In five of eight human transitional carcinoma cell (TCC) lines a proliferative response has been reported during exposure to interleukin-3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF). 8342256 Human
g-csf advanced cancer After informed consent, 86 patients with advanced cancer undergoing potentially myelosuppressive cytotoxic chemotherapy were randomized to receive placebo or subcutaneous granulocyte-colony stimulating factor (G-CSF) 5 micrograms/Kg/day in order to preven 7690396 Human
g-csf hematopoietic cell proliferation To explore the pathogenesis of marrow failure in B-cell type chronic lymphocytic leukemia (B-CLL), we have examined the production of interleukin-6 (IL-6), granulocyte colony-stimulating factor (G-CSF), and granulocyte-macrophage CSF (GM-CSF) by the adher 7691258 Human
g-csf recurrent non-hodgkin's lymphoma Twenty-three consecutive patients with recurrent non-Hodgkin's lymphoma received G-CSF (10.5 +/- 1.2 micrograms/kg per day) following myeloablative therapy consisting of etoposide (60 mg/kg), cyclophosphamide (100 mg/kg), and either carmustine (15 mg 7692189 Human
g-csf lung metastases As a control for IL-7, granulocyte colony stimulating factor (G-CSF) alone had no effect on primary tumor size or number of lung metastases. 8241952 Human
g-csf essential thrombocythemia [Effect of G-CSF and M-CSF on busulfan-induced marrow failure in a 91-year old patient with essential thrombocythemia] A 91-year-old patient with essential thrombocythemia presented with marked bone marrow suppression induced by long-term administration o 7508003 Human
g-csf myeloproliferative disorders BACKGROUND: Despite the fact that granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony-stimulating factor (G-CSF) are increasingly used in clinical practice, little is known of their endogenous production, especially in myelopr 15378942 Human
g-csf human osteosarcoma The effect of GM-CSF and G-CSF on the growth of human osteosarcoma cells in vitro and in vivo. 7508889 Human
g-csf human osteosarcoma The human osteosarcoma cell line, MG63, responds both to GM-CSF and to G-CSF in vitro. 7508889 Human
g-csf myelofibrosis [Hematologic abnormalities in a patient with chronic myelogenous leukemia with advanced myelofibrosis were improved by G-CSF] A 56-year-old woman was admitted with pyrexia, cough, and dyspnea on August 21, 1991. 7511182 Human
g-csf primitive neuroectodermal tumors The aim of the present study was to investigate by immunostaining the expression of the G-CSF protein within non-tumorous and tumorous glial tissues, and primitive neuroectodermal tumors. 7513314 Human
g-csf medulloblastoma Using the murine monoclonal anti-G-CSF TM 82/60 antibody, we found high G-CSF expression in astrocytoma WHO grades I and II and reactive brain tissue, low expression in astrocytoma WHO grade III, and none in glioblastoma, oligodendroglioma WHO grades II a 7513314 Mouse
g-csf transitional cell carcinoma of the bladder A patient presented with grade 3 transitional cell carcinoma of the bladder showing a marked increase in granulocyte colony-stimulating factor (G-CSF). 7513915 Human
g-csf gynecological cancers [Clinical evaluation of combined use of miconazole and G-CSF on deep-seated mycoses in patients with gynecological cancers] A combined therapy using miconazole (MCZ) and G-CSF was evaluated in clinical patients who developed deep-seated mycoses and fever 7515453 Human
g-csf gestational trophoblastic disease A novel strategy using G-CSF to support EMA/CO for high-risk gestational trophoblastic disease. 7529741 Human
g-csf gestational trophoblastic disease The addition of G-CSF to the EMA/CO regimen may benefit patients by achieving dose intensity in the treatment of high-risk gestational trophoblastic disease. 7529741 Human
g-csf paget disease [Paget disease, complicated by Ki-1 lymphoma with G-CSF growth factor secretion] Development of lysis within an area of pagetic bone suggests a sarcoma. 7532068 Human
g-csf ki-1 lymphoma [Paget disease, complicated by Ki-1 lymphoma with G-CSF growth factor secretion] Development of lysis within an area of pagetic bone suggests a sarcoma. 7532068 Human
g-csf t-all Receptor-binding for myeloid-associated GF was observed in the majority of precursor B-ALL (G-CSF = 100%, GM-CSF = 65%, IL-3 = 83%, SCF = 74%), but not in T-ALL. 7535143 Human
g-csf medulloblastoma Combined antitumor effects of TNF and G-CSF on a human medulloblastoma xenograft line. 7535346 Human
g-csf medulloblastoma The antitumor effects of TNF and G-CSF on a xenograft line of human medulloblastoma were examined. 7535346 Human
g-csf all in remission These results indicate G-CSFR+ B-cell precursors are markedly increased in BM of ALL in remission, suggesting the probable involvement of G-CSF in the human early B-cell ontogeny. 7734363 Human
g-csf metastatic tumors [Autologous stem cell harvesting after high dosage chemo- and/or growth factor therapy] 5 patients with metastatic tumors and 4 patients with hematological malignancies were treated either with G- or GM-CSF alone (5 micrograms/kg s.c.) or in combination w 7539197 Human
g-csf cns tumour Experiments were carried out in vitro to assess the risk of G-CSF causing increased CNS tumour cell proliferation. 7540401 Human
g-csf medulloblastomas 11 human CNS tumour cultures (2 medulloblastomas, 2 primitive neuroectodermal tumours and 7 astrocytic tumours) were cultured in the presence of G-CSF at a range of concentrations up to 100 ng/ml. 7540401 Human
g-csf primitive neuroectodermal tumours 11 human CNS tumour cultures (2 medulloblastomas, 2 primitive neuroectodermal tumours and 7 astrocytic tumours) were cultured in the presence of G-CSF at a range of concentrations up to 100 ng/ml. 7540401 Human
g-csf cns tumour 11 human CNS tumour cultures (2 medulloblastomas, 2 primitive neuroectodermal tumours and 7 astrocytic tumours) were cultured in the presence of G-CSF at a range of concentrations up to 100 ng/ml. 7540401 Human
g-csf ureter tumor The level of serum granulocyte colony-stimulating factor (G-CSF) assayed by enzyme immunoassay increased and the immunohistochemical staining of the ureter tumor showed the presence of G-CSF in tumor cells. 7571181 Human
g-csf ureter tumor To our knowledge, this is the first report of ureter tumor with leukocytosis producing G-CSF. 7571181 Human
g-csf ovarian tumor We evaluated the effects of recombinant human G-CSF, rhGM-CSF, rhM-CSF and rhIL-1 alpha on proliferation and regulation of c-jun gene expression in 4 human ovarian-carcinoma (HOC) cell lines, NIH:OVCAR-3, SK-OV-3, HEY and BG-1, and in one primary ovarian 7591243 Human
g-csf benign prostatic hypertrophy The levels of serum G-CSF in several patients with benign prostatic hypertrophy or urolithiasis were also elevated, but the mean levels were low. 8535676 Human
g-csf cll Five CLL B-cell fractions that released G-CSF following exposure to SAC were also incubated with CD40 or anti-mu antibodies in the presence or absence of recombinant (r) interleukin-2 (IL-2) or IL-4. 8639905 Human
g-csf cll The colony stimulating activity of CLL B-cell supernatants was ascribed to both G-CSF and granulocyte-macrophage colony stimulating factor. 8639905 Human
g-csf refractory non-hodgkin's lymphoma METHODS. Nineteen patients with metastatic breast cancer and six patients with refractory non-Hodgkin's lymphoma were initially treated with etoposide (VP-16) (2 gm/m2) and granulocyte-colony stimulating factor (G-CSF). 8625190 Human
g-csf large granular lymphocytosis Thus, Felty syndrome with large granular lymphocytosis is a heterogeneous condition, one in which TCR gamma delta large granular lymphocytosis may be found, and also shows a response to treatment with G-CSF. 8655718 Human
g-csf atll Vincristine 1 mg/m2 i.v. day 1, Adriamycin 40 mg/m2 i.v. day 1, cyclophosphamide 400 mg/m2 i.v. day 1, prednisolone 40 mg/m2 i.v. days 1 to 3 and 8 to 10, etoposide 35 mg/m2 i.v. days 1 to 8, vindesine 2 mg/m2 i.v. day 8, ranimustine 50 mg/m2 i.v. day 8, 8680890 Human
g-csf atll The G-CSF supported an intensified chemotherapy regimen for ATLL and yielded better response rate and longer survival compared to previous reports in Japan. 8680890 Human
g-csf refractory non-hodgkin's lymphoma Twenty-eight patients (14 with relapsing and 14 with refractory non-Hodgkin's lymphoma; NHL) were treated with a combination of CACE chemotherapy (cytosine arabinoside, carboplatin, and etoposide) and recombinant granulocyte colony-stimulating factor 8677759 Human
g-csf disseminated neuroblastoma Thus, granulocyte colony-stimulating factor (G-CSF) (filgrastim) given to children with disseminated neuroblastoma receiving intensive chemotherapy significantly reduced the duration of febrile neutropenia and led to significantly fewer cycles of chemothe 8750139 Human
g-csf ovarian cancer stage iii The clinical evaluation of human granulocyte colony-stimulating factor (G-CSF) in 38 patients treated with chemotherapy for ovarian cancer stage III was investigated among 3 groups. 8857232 Human
g-csf refractory non-hodgkin's lymphoma ACES (Ara-C, carboplatin, etoposide, steroids) therapy using granulocyte-colony stimulating factor (G-CSF) was designed for relapsed or refractory non-Hodgkin's lymphoma (NHL), and the therapeutic effects and adverse reactions were studied. 8982296 Human
g-csf gallbladder neoplasm [Case of G-CSF producing gallbladder neoplasm] 9019516 Human
g-csf malignant fibrous histiocytoma [A case of G-CSF producing malignant fibrous histiocytoma of the small intestine] 9170882 Human
g-csf stage iv non-small cell lung carcinoma This study sought to determine the principal toxicities and feasibility of administering paclitaxel as a 3-hour infusion followed by carboplatin without and with granulocyte colony-stimulating factor (G-CSF) in chemotherapy-naive patients with stage IV no 9220292 Human
g-csf adult all We conducted a prospective, randomized, controlled study to determine the safety and efficacy of granulocyte colony-stimulating factor (G-CSF; filgrastim) as an adjunct to phase I of induction chemotherapy for adult ALL. 9226158 Human
g-csf t-all Interestingly, T-ALL phenotype (p = 0.02) and higher neutrophil presentation count (p = 0.03) were associated with a shorter neutropenic course even with late G-CSF. 9250800 Human
g-csf crohn's disease This report confirms and extends one previous report of cyclic neutropenia associated with Crohn's disease and demonstrates in one patient the efficacy and safety of G-CSF on the hematologic, bacteriologic, and clinical manifestations of cyclic neutr 9252852 Human
g-csf rb In the present study we examined the effect of two different stimulants (fMLP, PMA) and three cytokines (alphaTNF, G-CSF and GM-CSF), both singly and in combination on granulocyte (RB) in 25 MDS patients compared to seven healthy controls. 9373205 Human
g-csf renal-cell carcinoma Histopathological diagnosis was renal cell carcinoma (Grade 3) and immunohistochemical staining using Histo anti-G-CSF antibody demonstrated cancer cells produced G-CSF. 9423336 Human
g-csf therapy-related mds Nineteen patients with high-risk myelodysplastic syndrome (MDS)/acute myeloid leukaemia (AML) received fludarabine, cytarabine, granulocyte-colony stimulating factor (G-CSF), and idarubicin chemotherapy (de novo MDS/MDS-AML, nine; relapsed/refractory MDS/ 9432047 Human
g-csf bone marrow hyperplasia G-CSF induced bone marrow hyperplasia: characteristic appearance on total body blood pool and delayed Tc-99m MDP bone scan. 9442966 Human
g-csf t-all In this study, we assessed the impact of r-metHu granulocyte colony-stimulating factor (G-CSF) on the period of neutropenia, number of days of hospitalization, and delays in subsequent administration of chemotherapy in a cohort of patients with T-cell leu 9469336 Human
g-csf lymphoid neoplasms Clinical value and costs of G-CSF administration following autograft with mobilized peripheral blood progenitor cells (PBPC) were evaluated in two sequential groups of 20 patients each, treated for lymphoid neoplasms in the period February 1993 to January 9509976 Human
g-csf secondary aml Two hundred thirty-four patients 55 or more years of age with a morphologic diagnosis of de novo or secondary AML, French-American-British (FAB) M0-M7, excluding M3, were randomly assigned to a standard induction regimen (daunorubicin at 45 mg/m2 intraven 9572995 Human
g-csf transitional cell carcinomas of the bladder In this review, G-CSF and tumor cell growth, particularly of human transitional cell carcinomas of the bladder, are discussed, and autocrine growth of human solid tumors is also summarized. 9681250 Human
g-csf uterine tumors METHODS: A total of 111 patients with ovarian, cervical, or endometrial carcinomas or benign ovarian or uterine tumors were enrolled on the study, and the levels of interleukin (IL)-2, IL-4, IL-6, IL-10, interferon (IFN)-gamma, granulocyte-colony stimulat 9708947 Human
g-csf aml IDA-FLAG (idarubicin, fludarabine, cytarabine, G-CSF), an effective remission-induction therapy for poor-prognosis AML of childhood prior to allogeneic or autologous bone marrow transplantation: experiences of a phase II trial. 9722289 Human
g-csf testicular germ-cell tumour Peptide growth factors involved in the regulation of haematopoiesis (HPGF), for example granulocyte-colony-stimulating factor (G-CSF) and granulocyte/macrophage-colony-stimulating factor (GM-CSF), are of clinical importance in the treatment of testicular 9750020 Human
g-csf refractory hodgkin's disease Twenty-six patients with relapsed or refractory Hodgkin's disease (HD) were treated with an intensive salvage regimen combining ifosfamide (3000 mg/m2/d, days 1-4 through continuous intravenous infusion) and vinorelbine (25 mg/m2, i.v. days 1 and 5) 9827930 Human
g-csf ain The good results in terms of neutrophils increment and infection prophylaxis render G-CSF attractive for treating AIN. 9844813 Human
g-csf stage iiib nsclc METHODS: 15 patients with functionally operable stage IIIB NSCLC (10 squamous-cell, 4 adeno, 1 large-cell) were enrolled to receive 4 cycles of docetaxel (100 mg/m2, day 1) and carboplatin (AUC 7.5, day 2) on an outpatient basis with G-CSF support after c 9885122 Human
g-csf relapsed non-hodgkin's lymphoma PURPOSE: To evaluate a chemotherapy regimen that consisted of ifosfamide administered as an infusion with bolus carboplatin, and etoposide (ICE) supported by granuloctye colony-stimulating factor (G-CSF) for cytoreduction and stem-cell mobilization in tra 10577849 Human
g-csf brain tumor The MTD achieved without granulocyte colony stimulating factor (G-CSF) was 3.5 mg/m2/day (DLT: neutropenia) and with G-CSF, it was as follows: patients with brain tumor, 4.2 mg/m2/day (DLT: myelosupression); and patients with solid tumor, 5 mg/m2/day (DLT 10598660 Human
g-csf refractory hodgkin's disease High dose chemotherapy with G-CSF in refractory Hodgkin's disease. 10613458 Human
g-csf bone marrow tumor The purpose of this study was to determine the efficacy, engraftment kinetics, effect of bone marrow tumor contamination, and safety of high-dose therapy and granulocyte-colony stimulating factor (G-CSF) mobilized peripheral blood progenitor cell (PBPC) s 10618691 Human
g-csf bladder tumor The prognosis of the reported cases of G-CSF producing bladder tumor has been very poor. 10659420 Human
g-csf pediatric all For pediatric ALL patients, this information indicates that G-CSF use is unlikely to have significant cost implications, and its use should be based on clinical considerations. 10721770 Human
g-csf adult aml In studies of adult and older adult AML patients, both GM-CSF and G-CSF have clinical benefits and can be expected to lead to a decrease in overall costs. 10721770 Human
g-csf childhood all CONCLUSION: G-CSF can increase CDI in high-risk childhood ALL. 10735900 Human
g-csf ain OBJECTIVE: To assess the role of granulocyte colony-stimulating factor (G-CSF) in autoimmune neutropenia (AIN). 10891829 Human
g-csf ain DESIGN: Serum G-CSF levels were measured in 57 children with AIN. 10891829 Human
g-csf ain The median G-CSF level in patients with AIN (n = 57) was very similar, 45.5 pg/mL (range <39 to 2500 pg/mL). 10891829 Human
g-csf ain CONCLUSION: G-CSF production in AIN is not increased despite the low neutrophil count, similar to thrombopoietin in immune thrombocytopenic purpura. 10891829 Human
g-csf adenocarcinoma of the breast PATIENTS AND METHODS: In the initial dose-escalation phase, 25 patients with adenocarcinoma of the breast (AB; 13 patients) or lymphoma (12 patients) were given daniplestim at doses ranging from 0.1 to 3.75 microgram/kg/d plus G-CSF 10 microgram/kg/d. 10894877 Human
g-csf oral tumor Both G-CSF preparations similarly enhanced the N-Formyl-Met-Leu-Phe-induced-migration of human peripheral blood polymorphonuclear cells, but did not significantly affect the proliferation of human oral tumor cell lines (HSC-2, HSG). 10953296 Human
g-csf medulloblastoma To evaluate its purging efficiency and engraftment data in the autologous transplant, PBSC from 28 adult patients with various malignant diseases (non-Hodgkin's lymphoma, n = 17; chronic lymphocytic leukemia, n = 5; multiple myeloma, n = 4; acute lym 10982256 Human
g-csf aggressive lymphoma Untreated patients with aggressive lymphoma under the age of 60 with two or three adverse prognostic factors (disseminated stage, increased serum LDH, ECOG performance status >1) were prospectively included between June 1995 and April 1998 in a trial eval 11187906 Human
g-csf recurrent nsclc These results clearly indicate that patients with endobronchial lesions from recurrent NSCLC could not tolerate this combined modality regimen without G-CSF support. 10210551 Human
g-csf ain Clinical value of granulocyte colony-stimulating factor (G-CSF) for autoimmune neutropenia (AIN) has not been well established. 10352336 Human
g-csf ain We experienced an adult case of AIN which showed an excellent response to G-CSF. 10352336 Human
g-csf oligodendrogliomas G-CSF expression was absent in all GFAP-negative tumors such as oligodendrogliomas. 10376937 Human
g-csf calgb High-dose paclitaxel plus G-CSF for malignant mesothelioma: CALGB phase II study 9234. 10416012 Human
g-csf epithelial skin tumors In the present study, we investigated the expression of G-CSFR or G-CSF in epithelial skin tumors by immunohistochemical staining. 11240265 Human
g-csf skin tumors There was significant positive correlation between the G-CSFR score and the G-CSF score (gamma=0.274, P=0.0107) in skin tumors. 11240265 Human
g-csf stage iii breast carcinoma METHODS: The authors investigated alterations of soluble CA 15-3 in 57 postoperative breast carcinoma patients while they were receiving intensified adjuvant chemotherapy with granulocyte colony stimulating factor (G-CSF) support; 26 patients had American 11251942 Human
g-csf non-hodgkin's lymphoma stage iv PBSC were harvested in a 44-year-old female patient with a low-grade non-Hodgkin's lymphoma stage IV after mobilization with chemotherapy and G-CSF. 11261320 Human
g-csf aids-related non-hodgkin's lymphoma Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. 11279624 Human
g-csf extensive stage sclc PATIENTS AND METHODS: One hundred thirty-three chemotherapy-naïve patients with histologically proven limited or extensive stage SCLC were randomised to receive either paclitaxel 175 mg/m2 i.v. three-hour infusion on day 1 and cisplatin 80 mg/m2 i.v. on 11398877 Human
g-csf mfh Prominent leukocytosis (up to 84,300/microl), a high serum G-CSF concentration (82 pg/ml) and positive immunohistochemical staining of the tumor tissue for G-CSF indicated that G-CSF was produced by the MFH. 11446682 Human
g-csf calgb CALGB 8852, a group-wide study, accrued 227 patients: 120 patients in the pilot study to determine the maximum tolerated dose (MTD) without G-CSF and 107 in the pilot study of dose-escalated CHOPE with G-CSF. 11466671 Human
g-csf calgb CALGB 8854, a limited-institution, Phase I study, enrolled 38 patients and determined the MTD of CHOPE with G-CSF to be used in CALGB 8852. 11466671 Human
g-csf refractory hodgkin's disease In an effort to improve results in patients with relapsed or refractory Hodgkin's disease (HD), an intensive regimen combining vinorelbine (25 mg/m2 i.v. days 1 and 5) and high-doses of ifosfamide (3000 mg/m2/d, days 1-4 by continuous infusion) with 11486403 Human
g-csf pediatric cancer To prevent serious infection, the use of G- or GM-CSF is recommended in a subset of pediatric cancer patients shortly after receiving chemotherapy or a marrow transplant. 11577368 Human
g-csf adult aml In order to determine whether granulocyte colony-stimulating factor (G-CSF) alone initiated during steady state was able to mobilize peripheral blood stem cells (PBSC) in acute myeloid leukemia (AML) and to assess predictive factors for engraftment after 11732869 Human
g-csf childhood non-hodgkin's lymphoma PURPOSE: To determine whether granulocyte colony-stimulating factor (G-CSF; lenograstim) decreases the incidence of febrile neutropenia after induction courses in treatment of childhood non-Hodgkin's lymphoma (NHL). 11786572 Human
g-csf childhood all A randomised study of prophylactic G-CSF following MRC UKALL XI intensification regimen in childhood ALL and T-NHL. 11813173 Human
g-csf t-cell non-hodgkins lymphoma PROCEDURE: Forty-six children with ALL or T-Cell non-Hodgkins lymphoma (NHL) treated on MRC ALL 97, UKALL XI or UKCCSG 9504 NHL protocols were randomised to receive granulocyte colony-stimulating factor following either the first or the second block of in 11813173 Human
g-csf childhood all CONCLUSIONS: This study shows that the prophylactic administration of G-CSF following intensification chemotherapy for childhood ALL and T-NHL produces a significant reduction in the rate of readmission to hospital for the management of febrile neutropeni 11813173 Human
g-csf ain In conclusion both glycosylated and nonglycosylated G-CSF can be used effectively in treating AIN on a long-term basis. 11985554 Human
g-csf germ-cell tumours Granulocyte colony-stimulating factor (G-CSF) levels were studied in 23 patients (10 myeloma, 13 relapsed Hodgkin's disease, non-Hodgkin's lymphoma or germ cell tumours), post autologous peripheral blood stem cell transplantation (PBSCT). 12028037 Human
g-csf secondary mds The present study suggests a close relationship between long-term use of G-CSF and secondary MDS in nonresponders to IST. 12130487 Human
g-csf therapy-related acute myeloid leukemia [Successful treatment with G-CSF and continuous infusion of low-dose cytarabine and etoposide for therapy-related acute myeloid leukemia developed during chemotherapy for malignant lymphoma] In March 2000, a 30-year-old Chinese male was initially diagnose 12134707 Human
g-csf adult acute myelogenous leukemia Prolonged administration of all-trans retinoic acid in combination with intensive chemotherapy and G-CSF for adult acute myelogenous leukemia: single-centre pilot study in different risk groups. 12189565 Human
g-csf advanced cancer The aim of this study was to determine the maximum tolerated dose of a fixed dose of docetaxel when combined with continuous infusion ifosfamide, with and without G-CSF support, in the treatment of advanced cancer, and to evaluate anti-tumour activity of 12373597 Human
g-csf aml The aim of this study was to evaluate G-CSF receptor (G-CSFr) expression on myeloid blasts, its prognostic significance and role in growth factor use and the safety and efficacy of G-CSF in the treatment of AML. 12802915 Human
g-csf b-cell non-hodgkin's lymphoma Treatment of relapsed B-cell non-Hodgkin's lymphoma with a combination of chimeric anti-CD20 monoclonal antibodies (rituximab) and G-CSF: final report on safety and efficacy. 12886256 Human
g-csf treatment-related aml Patients treated with AC with intensified doses of cyclophosphamide requiring G-CSF support had increased rates of treatment-related AML/MDS, even though the incidence was slight relative to breast cancer relapse. 14651772 Human
g-csf ain AIM: To investigate the role of granulocyte colony-stimulating factor (G-CSF) and adhesion molecules and the response of bone marrow to peripheral cytopenia in autoimmune neutropenia of childhood (AIN). 14696847 Human
g-csf undifferentiated acute leukemia We describe a case of a patient with CD34+, TdT+, CD13-, CD33-, MPO- undifferentiated acute leukemia who refused chemotherapy and who achieved complete hematological remission 14 months after the diagnosis, during a short course of granulocyte-colony stim 14959860 Human
g-csf acute leukemia Finally, the patient developed progressive neutropenia, anemia, thrombocytopenia and acute leukemia in spite of G-CSF therapy, dying 64 months after initial diagnosis (50 months after starting G-CSF therapy) with overt G-CSF resistant acute myeloblastic l 14959860 Human
g-csf ibd G-CSF treatment and g.d.f. can be protective factors for IBD. 14971792 Human
g-csf lung tumor In our study, we first reported that serum deprivation stimulated constitutive production of G-CSF and GM-CSF by lung tumor cells through activation of nuclear factor (NF)-kappaB and p44/42 mitogen-activated protein kinase (MAPK) pathway signaling. 15027115 Human
g-csf b-cell non-hodgkin's lymphoma Peripheral blood stem cell mobilization following CHOP plus rituximab therapy combined with G-CSF in patients with B-cell non-Hodgkin's lymphoma. 14743197 Human
g-csf precancerous state Unlike complete or 50% loss, 80% loss of PU.1 induced a precancerous state characterized by accumulation of an abnormal precursor pool retaining responsiveness to G-CSF with disruption of M- and GM-CSF pathways. 15146183 Human
g-csf meningiomas Expression of G-CSF and GM-CSF in human meningiomas correlates with increased tumor proliferation and vascularization. 15218949 Human
g-csf meningioma Therefore, we analyzed immunohistochemically the protein expression of G-CSF, GM-CSF and their respective receptors in 30 meningioma tissues of different malignancy and histopathological type. 15218949 Human
g-csf meningiomas In contrast, G-CSF, GM-CSF and their receptors were expressed to a varying degree in human meningiomas. 15218949 Human
g-csf polycythaemia vera As the clinical significance of CD177 expression is unknown, we investigated its expression in healthy individuals before and after stimulation with granulocyte colony-stimulating factor (G-CSF), in patients with rheumatoid arthritis, viral hepatitis, sev 15238147 Human
g-csf high-grade lymphoma METHODS: Twenty-two patients with resected early breast carcinoma and 6 patients with high-grade lymphoma received chemotherapy cycles with or without G-CSF support. 15386335 Human
g-csf follicular lymphoma EXPERIMENTAL DESIGN: We administered rituximab with CHOP (cyclophosphamide, doxorubicin, vincristine, prednisone) treatment with G-CSF to 15 patients with follicular lymphoma, and we investigated the safety and efficacy of this regimen. 15217942 Human
g-csf acute myelomonocytic leukemia Transient atypical monocytosis mimic acute myelomonocytic leukemia in post-chemotherapy patients receiving G-CSF: report of two cases. 15485468 Human
g-csf skin squamous cell carcinomas We demonstrated previously that tumor progression in patients and in the experimental HaCaT tumor model for skin squamous cell carcinomas is associated with a constitutive neoexpression of the hematopoietic growth factors granulocyte colony-stimulating fa 15520186 Human
g-csf benign tumor To analyze the critical contribution of both factors to tumor progression, G-CSF or GM-CSF was stably transfected in factor-negative benign tumor cells. 15520186 Human
g-csf pediatric acute myeloid leukemia The effect of G-CSF on the in vitro cytotoxicity of cytarabine and fludarabine in the FLAG combination in pediatric acute myeloid leukemia. 15547723 Human
g-csf pediatric cancer G-CSF has been used to treat neutropenia in neonates, pediatric cancer patients, and patients undergoing stem cell transplantation. 15557108 Human
g-csf b-cell non-hodgkin lymphoma We pooled the results of 3 prospective phase 2 trials evaluating rituximab in combination with 96-hour infusion of cyclophosphamide (187.5-200 mg/m2 per day), doxorubicin (12.5 mg/m2 per day), and etoposide (60 mg/m2 per day) (R-CDE) plus granulocyte-colo 15550484 Human
g-csf malignant pleural mesothelioma We report a 65-year-old man with malignant pleural mesothelioma that produced granulocyte colony-stimulating factor (G-CSF) and other cytokines. 15729603 Human
g-csf malignant mesothelioma Malignant mesothelioma may produce G-CSF and other cytokines. 15729603 Human
g-csf squamous cell carcinoma of bladder [Squamous cell carcinoma of bladder producing granulocyte colony-stimulating factor (G-CSF): a case report] A case of bladder squamous cell cancer producing granulocyte colony-stimulating factor (G-CSF) is reported. 15773367 Human
g-csf squamous-cell cancer [Squamous cell carcinoma of bladder producing granulocyte colony-stimulating factor (G-CSF): a case report] A case of bladder squamous cell cancer producing granulocyte colony-stimulating factor (G-CSF) is reported. 15773367 Human
g-csf anaplastic astrocytoma CONCLUSION: Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma. 15735921 Human
g-csf glioblastoma CONCLUSION: Paclitaxel and topotecan with G-CSF support exhibits modest activity in adults with recurrent or refractory glioblastoma and anaplastic astrocytoma. 15735921 Human
g-csf axillary metastasis KT293, a S100, gp100 and CD68 positive melanoma cell line derived from an axillary metastasis, produced large amounts of G-CSF in vitro and induced rapidly growing tumors and PLR after subcutaneous inoculation in SCID mice. 15662134 Mouse
g-csf adenosquamous carcinoma of the stomach We report a case of adenosquamous carcinoma of the stomach that produced granulocyte-colony stimulating factor (G-CSF). 16086120 Human
g-csf adenosquamous carcinoma The resected stomach tumor was histologically diagnosed as adenosquamous carcinoma; positive expression of G-CSF by tumor cells was shown with immunohistochemical detection, which confirmed the preoperative diagnosis. 16086120 Human
g-csf stomach tumor The resected stomach tumor was histologically diagnosed as adenosquamous carcinoma; positive expression of G-CSF by tumor cells was shown with immunohistochemical detection, which confirmed the preoperative diagnosis. 16086120 Human
g-csf lymph-node metastases A 57-year-old Japanese man had type II c gastric cancer with marked lymph node metastases associated with leukocytosis and elevated granulocyte colony-stimulating factor (G-CSF). 16086124 Human
gcsf carcinoid tumors METHODS: Twenty-four patients (14 with carcinoid tumors, 9 with islet cell tumors, and 1 with an anaplastic tumor) were enrolled on this Phase II study of paclitaxel given as a 24-hour continuous infusion at a dose of 250 mg/m(2) every 3 weeks plus GCSF a 11301403 Human
gcsf ibd Patients with glycogen storage disease type 1b (GSD-1b) have neutropenia and neutrophil dysfunction that predispose to frequent infections and inflammatory bowel disease (IBD), for which granulocyte colony-stimulating factor (GCSF) is given. 12373578 Human
g-csf acquired aplastic anemias [Time course changes in the count of peripheral granulocytes in children with acquired aplastic anemias treated with antithymocyte globulin, cyclosporin A and granulocytic colony stimulating factor] AIM: To examine the pattern of changes in the count of p 12577848 Human
granulocyte colony stimulating factor bladder tumor [Two cases of bladder tumor producing granulocyte colony stimulating factor] Two cases of bladder tumor producing granulocyte colony-stimulating factor (G-CSF) are reported. 10086269 Human
granulocyte colony stimulating factor brain tumor The MTD achieved without granulocyte colony stimulating factor (G-CSF) was 3.5 mg/m2/day (DLT: neutropenia) and with G-CSF, it was as follows: patients with brain tumor, 4.2 mg/m2/day (DLT: myelosupression); and patients with solid tumor, 5 mg/m2/day (DLT 10598660 Human
granulocyte colony stimulating factor urological cancer [Optimal way of administration of granulocyte colony stimulating factor in the treatment of urological cancer] Granulocyte-Colony Stimulating Factor (G-CSF) was administered to patients with bladder cancer, ureteral cancer and testicular cancer following 7684099 Human
granulocyte colony stimulating factor transitional carcinoma In five of eight human transitional carcinoma cell (TCC) lines a proliferative response has been reported during exposure to interleukin-3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF). 8342256 Human
granulocyte colony stimulating factor transitional cell carcinoma [Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy] We determined the effective method of administrat 7685138 Human
granulocyte colony stimulating factor squamous cell carcinoma of urinary bladder Problems in early diagnosis of bladder cancer in a spinal cord injury patient: Report of a case of simultaneous production of granulocyte colony stimulating factor and parathyroid hormone-related protein by squamous cell carcinoma of urinary bladder. 12201902 Human
granulocyte colony stimulating factor primary tumor As a control for IL-7, granulocyte colony stimulating factor (G-CSF) alone had no effect on primary tumor size or number of lung metastases. 8241952 Human
filgrastim large granular lymphocytosis Treatment of chronic neutropenia associated with large granular lymphocytosis with cyclosporine A and filgrastim. 7485104 Human
filgrastim pediatric cancer Treating febrile neutropenia in pediatric cancer patients at home is effective and cost-efficient if the patients are clinically stable and prophylactic filgrastim therapy has been started after the completion of cancer chemotherapy. 8846241 Human
filgrastim disseminated neuroblastoma Thus, granulocyte colony-stimulating factor (G-CSF) (filgrastim) given to children with disseminated neuroblastoma receiving intensive chemotherapy significantly reduced the duration of febrile neutropenia and led to significantly fewer cycles of chemothe 8750139 Human
filgrastim aids-related non-hodgkin's lymphoma BACKGROUND: A phase I/II trial determined the maximum tolerated dose (MTD) of CEOP for AIDS-related non-Hodgkin's lymphoma (NHL) with concurrent filgrastim and antiretroviral therapy. 9037361 Human
filgrastim advanced cancer Randomized, blinded, placebo-controlled phase I trial of pegylated recombinant human megakaryocyte growth and development factor with filgrastim after dose-intensive chemotherapy in patients with advanced cancer. 9129014 Human
filgrastim advanced cancers We administered PEG-rHuMGDF with filgrastim after dose-intensive chemotherapy to 41 patients with advanced cancers to determine its safety and effects on hematologic recovery. 9129014 Human
filgrastim adult all We conducted a prospective, randomized, controlled study to determine the safety and efficacy of granulocyte colony-stimulating factor (G-CSF; filgrastim) as an adjunct to phase I of induction chemotherapy for adult ALL. 9226158 Human
filgrastim advanced cancer Phase I-II study of dose intensified chemotherapy with filgrastim and thymopentin in patients with advanced cancer. 9377855 Human
filgrastim advanced cancer Phase I and pharmacokinetic study of KRN8602 alone and with filgrastim in patients with advanced cancer. 9626219 Human
filgrastim calgb A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. 9716583 Human
filgrastim cll Fludarabine, cyclophosphamide, and filgrastim make up a highly active and well-tolerated regimen in CLL and NHL. 10891432 Human
filgrastim advanced cancer PATIENTS AND METHODS: In this open-label study, 68 patients with advanced cancer were randomized to receive PEG-rHuMGDF subcutaneously at different doses and durations before administration of carboplatin 600 mg/m(2), cyclophosphamide 1,200 mg/m(2), and f 10920133 Human
filgrastim hcl Filgrastim regularly increases the ANC in patients with HCL and shortens the duration of severe neutropenia after cladribine. 10194424 Human
filgrastim aids-related non-hodgkin's lymphoma Oral combination chemotherapy in conjunction with filgrastim (G-CSF) in the treatment of AIDS-related non-Hodgkin's lymphoma: evaluation of the role of G-CSF; quality-of-life analysis and long-term follow-up. 11279624 Human
filgrastim medulloblastoma We compared the efficacy, toxicity, and cost of topotecan-filgrastim and filgrastim alone for mobilizing peripheral blood stem cells (PBSCs) in 24 consecutive pediatric patients with newly diagnosed medulloblastoma. 11607769 Human
filgrastim squamous cell carcinoma of the head and neck Phase II trial of dose-dense paclitaxel, cisplatin, 5-fluorouracil, and leucovorin with filgrastim support in patients with squamous cell carcinoma of the head and neck. 15305408 Human
filgrastim endometrial carcinoma Phase III randomized trial of doxorubicin + cisplatin versus doxorubicin + 24-h paclitaxel + filgrastim in endometrial carcinoma: a Gynecologic Oncology Group study. 15277255 Human
filgrastim endometrial cancer BACKGROUND: This study was performed to determine whether 24-h paclitaxel plus doxorubicin and filgrastim was superior to cisplatin plus doxorubicin in patients with endometrial cancer with respect to response, progression-free survival (PFS) and overall 15277255 Human
filgrastim anaplastic astrocytoma A Phase II trial of paclitaxel and topotecan with filgrastim in patients with recurrent or refractory glioblastoma multiforme or anaplastic astrocytoma. 15735921 Human
filgrastim refractory chronic lymphocytic leukemia Filgrastim and alemtuzumab (Campath-1H) for refractory chronic lymphocytic leukemia. 15858611 Human
lenograstim childhood non-hodgkin's lymphoma PURPOSE: To determine whether granulocyte colony-stimulating factor (G-CSF; lenograstim) decreases the incidence of febrile neutropenia after induction courses in treatment of childhood non-Hodgkin's lymphoma (NHL). 11786572 Human
pluripoietin necrosis Effects of recombinant human tumor necrosis factor alpha, recombinant human gamma-interferon, and prostaglandin E on colony formation of human hematopoietic progenitor cells stimulated by natural human pluripotent colony-stimulating factor, pluripoietin a 3089590 Human
pluripoietin necrosis The influences of pure human pluripotent colony-stimulating factor, highly purified pluripoietin alpha, pure recombinant human tumor necrosis factor alpha, pure recombinant human gamma-interferon, and natural prostaglandin E1 (PGE1) were evaluated on colo 3089590 Human
granulocyte colony stimulating factor mec [Effect of recombinant human granulocyte colony stimulating factor in patients with transitional cell carcinoma of the urothelium receiving methotrexate, etoposide and cisplatinum combination chemotherapy] We determined the effective method of administrat 7685138 Human
g-csf erythroleukemia IL-3, IL-1, IL-4, IL-6, GM colony-stimulating factor (GM-CSF), G-CSF, M-CSF, Ep, and media conditioned by concanavalin A-stimulated mouse spleen cells or phytohemagglutinin-stimulated LBRM 33 cells were unable to induce proliferation of the Rauscher eryth 2653464 Mouse
g-csf osteosarcoma These data indicate that GM-CSF and G-CSF can support the growth of an osteosarcoma cell line both in vitro and in vivo whether the factor is supplied by autocrine production or from exogenous sources. 7508889 Human
g-csf urological cancer [Optimal way of administration of granulocyte colony stimulating factor in the treatment of urological cancer] Granulocyte-Colony Stimulating Factor (G-CSF) was administered to patients with bladder cancer, ureteral cancer and testicular cancer following 7684099 Human
g-csf testicular tumor In EP chemotherapy against testicular tumor, G-CSF was started on the 9th day and continued for 5 days. 7684099 Human
g-csf urological cancer G-CSF is proposed to be enrolled in the treatment of urological cancer for the improvement of safety and the outcome of therapy. 7684099 Human
g-csf mec Recombinant human G-CSF was administered at 2 micrograms/kg subcutaneously starting after the white blood cell count was less than 3,000/mm3 (short administration) or starting immediately after finishing MEC therapy (prophylactic administration). 7685138 Human
g-csf juvenile chronic myelogenous leukemia In vitro colony assay also suggests an increase in sensitivity of GM progenitors to cytokines (GM-CSF, IL-3, G-CSF and/or SCF) in a patient with juvenile chronic myelogenous leukemia. 7686232 Human
g-csf large cell carcinoma [Granulocyte colony-stimulating factor producing lung large cell carcinoma with sarcomatous transformation] We report a case of granulocyte colony-stimulating factor (G-CSF) producing lung large cell carcinoma with sarcomatous transformation. 1279257 Human
g-csf burkitt's lymphoma One of the patients developed a tumour-like infiltration in his left upper jaw, which histologically simulated Burkitt's lymphoma and which regressed spontaneously after discontinuation of the G-CSF therapy. 1281810 Human
g-csf acute megakaryoblastic leukemia [Induction of complete remission in a case of drug-resistant childhood acute megakaryoblastic leukemia by combination of G-CSF and chemotherapy] In a 4-year-old girl having acute megakaryoblastic leukemia, recombinant human granulocyte colony-stimulating 1374487 Human
g-csf transitional cell carcinoma (tcc) To elucidate possible growth-modulating effects of interleukin 3 (IL-3), granulocyte-macrophage-colony-stimulating factor (GM-CSF) and granulocyte-colony-stimulating factor (G-CSF), human transitional cell carcinoma (TCC) cell lines T24, RT112, EJ and 647 1380747 Human
g-csf giant cell tumor In order to obtain more insight into the nature of the abnormal in vitro colony formation in myelodysplastic syndromes (MDS), we investigated the kinetics of the colony formation of 23 MDS cases in response to recombinant human interleukin-3 (IL-3), Granu 1694940 Human
g-csf giant cell carcinoma A patient with pleomorphic giant cell carcinoma of the gallbladder also had mild neutrophilia, and this tumor was found to be human granulocyte colony-stimulating factor (G-CSF)-positive on immunohistochemical staining. 1703976 Human
g-csf testicular tumors In conclusion, BEP chemotherapy is effective to EGGCT as well as far advanced testicular tumors and G-CSF treatment is useful for achievement of induction chemotherapy to advanced germ cell tumors. 1723842 Human
g-csf malignant mesotheliomas Nine patients were not evaluable because 3 patients were treated with combination of other antibiotics such as ceftizoxime, norfloxacin, ofloxacin, 1 patient was subjected to additional therapy of G-CSF and gamma-globulin, 4 were the patients with other d 2283706 Human
g-csf acute myelomonocytic leukemia (ammol) Two patients with acute myelomonocytic leukemia (AMMoL) were tested to determine whether or not their cells produced granulocyte colony-stimulating factor (G-CSF). 2461497 Human
g-csf acute myelomonocytic leukemia (ammol) In contrast, linear dose responses parallel to a G-CSF standard curve were observed in one patient with a severe bacterial infection, four with aplastic anemia, two with acute myelomonocytic leukemia (AMMoL) (M4), and two with idiopathic neutropenia teste 2463930 Human
granulocyte colony stimulating factor ureteral cancer [Optimal way of administration of granulocyte colony stimulating factor in the treatment of urological cancer] Granulocyte-Colony Stimulating Factor (G-CSF) was administered to patients with bladder cancer, ureteral cancer and testicular cancer following 7684099 Human
g-csf monocyte tumoricidal activity In this study, the effects of three recombinant human CSFs (granulocyte-monocyte CSF [GM-CSF], interleukin 3 [IL-3], and granulocyte CSF [G-CSF]) on antibody-independent monocyte tumoricidal activity were investigated by using WEHI 164 fibrosarcoma cells 3278752 Human
g-csf ureteral cancer [Optimal way of administration of granulocyte colony stimulating factor in the treatment of urological cancer] Granulocyte-Colony Stimulating Factor (G-CSF) was administered to patients with bladder cancer, ureteral cancer and testicular cancer following 7684099 Human
g-csf murine colon adenocarcinoma Using the murine colon adenocarcinoma C-26 cell line, engineered to release granulocyte colony-stimulating factor (G-CSF) (C-26/G-CSF), were studied the mechanisms responsible for inhibition of tumor take in syngeneic animals and of regression of an estab 7686211 Human
g-csf urogenital cancers [Use of G-CSF in chemotherapy of urogenital cancers] 7686286 Human
g-csf tumour-induced hypercalcemia Bone resorbing factors like the cytokines-lymphokines, interleukins, prostaglandins, TNF-alpha/TNF-beta, GM-CSF/G-CSF, TGF-alpha and TGF-beta are produced by certain solid and hematologic cancers and have also been implicated in tumour-induced hypercalcem 8352538 Human
g-csf urogenital cancers We evaluated the efficacy and safety of recombinant human granulocyte colony-stimulating factor (G-CSF) in patients with leukopenia after chemotherapy for urogenital cancers. 1372661 Human
g-csf urogenital cancer The results indicate that recombinant human G-CSF may be safely and effectively used against leukopenia after chemotherapy for urogenital cancer. 1372661 Human
g-csf murine colon adenocarcinoma We have previously demonstrated that the murine colon adenocarcinoma C-26 cell line transduced with the human gene for the granulocyte CSF (G-CSF) loses tumorigenic activity through a mechanism that involved massive targeting of neutrophils at the site of 1376745 Human
g-csf pulmonary cancers To evaluate the toxicity and efficacy of recombinant human granulocyte-colony-stimulating factor (rh G-CSF) administered with intensive chemotherapy, 39 patients with advanced pulmonary cancers were enrolled in a dose escalation trial of rh G-CSF. 2475245 Human
g-csf b acute lymphoblastic leukemia We have tested a panel of recombinant hematopoietic growth factors (HGF) including the interleukins (IL) 1, 2, 3, 4, and 6 and the colony stimulating factors GM-CSF, G-CSF, M-CSF for their ability to induce proliferation of precursor B acute lymphoblastic 2497281 Human
granulocyte colony stimulating factor kaposi sarcoma [Granulocyte colony stimulating factor (G-CSF) in treatment of patients with HIV-associated mucocutaneous Kaposi sarcoma. 1281810 Human
granulocyte colony stimulating factor chronic myeloproliferative disorder [Sweet's syndrome in a patient with chronic myeloproliferative disorder during recombinant human granulocyte colony stimulating factor therapy] A patient with chronic myeloproliferative disorder (CMPD) developed Sweet's syndrome during granulocy 7540225 Human
granulocyte colony stimulating factor lung metastases As a control for IL-7, granulocyte colony stimulating factor (G-CSF) alone had no effect on primary tumor size or number of lung metastases. 8241952 Human
granulocyte colony stimulating factor stage iii breast carcinoma METHODS: The authors investigated alterations of soluble CA 15-3 in 57 postoperative breast carcinoma patients while they were receiving intensified adjuvant chemotherapy with granulocyte colony stimulating factor (G-CSF) support; 26 patients had American 11251942 Human
g-csf functional living indexcancer (flic) The following analyses were undertaken: (1) evaluation of toxicity and efficacy parameters for patients in the current (NHL-2) study; (2) analysis of the clinical role of G-CSF by (historical) comparison with the NHL-1 study of the same regimen without G- 11279624 Human
filgrastim malignant germ cell tumors CONCLUSION: During combination chemotherapy in patients with malignant germ cell tumors, the routine use of filgrastim significantly improved the delivery of the planned treatment schedule without effect on failure-free or overall survival. 9469362 Human
filgrastim mantle cell lymphoma A 49-year-old man with mantle cell lymphoma received 2.5 g/m2 of cyclophosphamide and 900 mg/m2 of etoposide followed by 10 microg/kg/day of Filgrastim for PBPC mobilization. 9603411 Human
filgrastim rectal cancer In the Oncologic Radiotherapy Department of Treviso Hospital, 31 patients irradiated for Hodgkin disease, rectal cancer and other malignancies, who presented leukopenia requiring treatment discontinuation, were given filgrastim to assess its actual effect 9638171 Human
filgrastim hairy cell leukemia Filgrastim for cladribine-induced neutropenic fever in patients with hairy cell leukemia. 10194424 Human
filgrastim stage ii breast cancer PATIENTS AND METHODS: Women with stage II breast cancer and 10 or more involved nodes or four or more involved nodes and estrogen receptor-negative tumors and women with stage III disease received three cycles of epirubicin 200 mg/m2 and cyclophosphamide 10458221 Human
filgrastim cancer of the testis The yield of CD34+ PBPC and colony-forming units-granulocyte-macrophage (CFU-GM) in leukapheresis products and the expression of the adhesion molecules CD11a, CD31, CD49d, CD49e, CD54, CD58, CD62L, c-kit (CD117), Thy-1 (CD90), CD33, CD38, and HLA-DR on CD 10791904 Human
filgrastim accelerated phase cml To assess the possibility of stem cell mobilization (SCM) during imatinib therapy we performed granulocyte colony-stimulating factor (filgrastim)-induced SCM and subsequent aphaeresis in 15 chronic phase and three accelerated phase CML patients. 14687030 Human
granulocyte colony stimulating factor cmpd [Sweet's syndrome in a patient with chronic myeloproliferative disorder during recombinant human granulocyte colony stimulating factor therapy] A patient with chronic myeloproliferative disorder (CMPD) developed Sweet's syndrome during granulocy 7540225 Human
granulocyte colony stimulating factor intermediate grade lymphoma The purpose of this study was to assess the safety and feasibility of using standard and escalated doses of cyclophosphamide with doxorubicin, vincristine and prednisone (CHOP) plus granulocyte colony stimulating factor (G-CSF) to treat elderly patients w 9711921 Human
granulocyte colony stimulating factor acute myelogenous leukaemia (aml) A phase II trial was designed to explore the potential feasibility and efficacy of a reinduction therapy consisting of fludarabine, cytarabine, idarubicin and granulocyte colony stimulating factor (G-CSF) for acute myelogenous leukaemia (AML) patients wit 9722289 Human
granulocyte colony stimulating factor pleomorphic carcinoma [Pleomorphic carcinoma of the lung with high serum granulocyte colony stimulating factor, suggested of pulmonary abscess by preoperative radiology; report of a case] A 52-year-old man with a history of heavy smoking was hospitalized for evaluation of feve 16922448 Human
g-csf thymoma A study was conducted to evaluate the impact of cisplatin, doxorubicin, cyclophosphamide and etoposide (PACE) with granulocyte colony-stimulating factor (G-CSF) on advanced thymoma or thymic cancer. 7474409 Human
g-csf thymoma Between August 1989 and December 1994, 14 patients with invasive, metastatic or recurrent thymoma or thymic cancer were treated with cisplatin (80 mg/m2, on day 1), doxorubicin (45 mg/m2, on day 1), cyclophosphamide (800 mg/m2, on day 1) and etoposide (80 7474409 Human
g-csf thymoma In conclusion, PACE with G-CSF frequently produces objective remissions in patients with advanced thymoma or thymic cancer. 7474409 Human
g-csf recurrent tumor The autopsy showed that the recurrent tumor had positive immunohistochemical staining for G-CSF, and the bone marrow had reactive proliferation mainly by granulocytes. 7521443 Human
g-csf cyst [The expression of granulocyte colony-stimulating factor in malignant gliomas] In this study, we investigated the expression of granulocyte colony-stimulating factor (G-CSF), G-CSF mRNA, G-CSF receptor mRNA in glioma cell lines, G-CSF in glioma cyst fluid 7530027 Human
g-csf malignant gliomas [The expression of granulocyte colony-stimulating factor in malignant gliomas] In this study, we investigated the expression of granulocyte colony-stimulating factor (G-CSF), G-CSF mRNA, G-CSF receptor mRNA in glioma cell lines, G-CSF in glioma cyst fluid 7530027 Human
g-csf cyst To determine whether G-CSF was produced in vivo, we analyzed the presence of G-CSF by ELISA in five glioma cyst fluids, but G-CSF was not detected in any. 7530027 Human
g-csf chronic myeloproliferative disorder [Sweet's syndrome in a patient with chronic myeloproliferative disorder during recombinant human granulocyte colony stimulating factor therapy] A patient with chronic myeloproliferative disorder (CMPD) developed Sweet's syndrome during granulocy 7540225 Human
g-csf cmpd [Sweet's syndrome in a patient with chronic myeloproliferative disorder during recombinant human granulocyte colony stimulating factor therapy] A patient with chronic myeloproliferative disorder (CMPD) developed Sweet's syndrome during granulocy 7540225 Human
g-csf acute myeloblastic leukemia (aml) The suppressive effect by TGF-beta 1 was increased for growth with GM-CSF, IL-3, and SCF, and growth with G-CSF was unaffected in hematologic malignancies, TGF-beta 1 suppression for growth with G-CSF was increased for essential thrombocythemia (ET) and p 7543418 NA
g-csf chronic myelogenous leukemia (cml) The suppressive effect by TGF-beta 1 was increased for growth with GM-CSF, IL-3, and SCF, and growth with G-CSF was unaffected in hematologic malignancies, TGF-beta 1 suppression for growth with G-CSF was increased for essential thrombocythemia (ET) and p 7543418 NA
g-csf cml The suppressive effect by TGF-beta 1 was increased for growth with GM-CSF, IL-3, and SCF, and growth with G-CSF was unaffected in hematologic malignancies, TGF-beta 1 suppression for growth with G-CSF was increased for essential thrombocythemia (ET) and p 7543418 NA
g-csf essential thrombocythemia (et) The suppressive effect by TGF-beta 1 was increased for growth with GM-CSF, IL-3, and SCF, and growth with G-CSF was unaffected in hematologic malignancies, TGF-beta 1 suppression for growth with G-CSF was increased for essential thrombocythemia (ET) and p 7543418 Human
g-csf mesothelioma Chronic myelogenous leukemia (CML) associated with granulocyte colony-stimulating factor (G-CSF)-producing mesothelioma. 7544855 Human
g-csf skin tumors In addition, skin tumors developed on his extremities and chest 14 days after the second use of G-CSF. 7823397 Human
g-csf skin tumors Before the development of the tumors we administered G-CSF, which may also have been related to the formation of the skin tumors. 7823397 Human
g-csf mediastinal tumour A 68-year-old man was diagnosed as having a granulocyte colony-stimulating factor (G-CSF)-producing mediastinal tumour. 8555056 Human
g-csf primary lung tumor Immunohistochemical staining with an anti-G-CSF monoclonal antibody to the primary lung tumor and the gingival mass obtained at autopsy was positive for cytoplasmic G-CSF. 8583722 Human
g-csf follicular non-hodgkin's lymphoma We have evaluated CD34+ cell positive selection from granulocyte-colony stimulating factor (G-CSF)-mobilized peripheral blood progenitor cells (PBPC) in 26 patients with either multiple myeloma (MM, n = 18) or follicular non-Hodgkin's lymphoma (NHL, 8602984 Human
g-csf b-cell chronic lymphocytic leukemia (b-cll) B lymphocytes were purified from the peripheral blood of 30 B-cell chronic lymphocytic leukemia (B-CLL) patients and tested for the ability to produce granulocyte colony-stimulating factor (G-CSF) in vitro. 8639905 Human
g-csf follicular lymphoma Three patients (two with chronic lymphocytic leukemia and one with follicular lymphoma) with massive bone marrow infiltration and neutropenia not caused by short-term effects of chemotherapy, were treated with G-CSF for five two-week periods, to find out 8644050 Human
g-csf adult t-cell leukemia SUMMARY: An intensive combination chemotherapy regimen supported by granulocyte colony-stimulating factor (G-CSF) was evaluated in adult T-cell leukemia/lymphoma (ATLL) patients in a multiinstitutional, cooperative study. 8680890 Human
g-csf atll SUMMARY: An intensive combination chemotherapy regimen supported by granulocyte colony-stimulating factor (G-CSF) was evaluated in adult T-cell leukemia/lymphoma (ATLL) patients in a multiinstitutional, cooperative study. 8680890 Human
g-csf blast crisis Fifty seven patients with acute leukemia (35 cases of refractory acute myeloid leukemia, 19 cases of acute lymphoblastic leukemia and 3 cases of blast crisis of chronic myeloid leukemia) were given G-CSF under either of the following two conditions; 1) Gr 8691565 Human
g-csf murine leukemia We found that G-CSF leads to apoptosis of radiation induced murine leukemia cell line (C2M-A5), and its apoptosis is dependent on cell cycle. 8741669 Mouse
g-csf myelofibrosis Administration of EPO and G-CSF may have led to the rapid development of leukemia and myelofibrosis. 8779784 Human
g-csf adult t-cell leukemia [An intensive chemotherapy of adult T-cell leukemia/lymphoma] An intensive combination chemotherapy regimen supported by granulocyte colony-stimulating factor (G-CSF) was evaluated in 81-adult T-cell leukemia/lymphoma (ATLL) patients in a multi-institutio 8827873 Human
g-csf atll [An intensive chemotherapy of adult T-cell leukemia/lymphoma] An intensive combination chemotherapy regimen supported by granulocyte colony-stimulating factor (G-CSF) was evaluated in 81-adult T-cell leukemia/lymphoma (ATLL) patients in a multi-institutio 8827873 Human
g-csf t-cell leukemia [An intensive chemotherapy of adult T-cell leukemia/lymphoma] An intensive combination chemotherapy regimen supported by granulocyte colony-stimulating factor (G-CSF) was evaluated in 81-adult T-cell leukemia/lymphoma (ATLL) patients in a multi-institutio 8827873 Human
g-csf chronic neutrophilic leukemia (cnl) It is clearly demonstrated that serum G-CSF levels of the patients with PMF and chronic neutrophilic leukemia (CNL) are extremely low, similar to those in patients with CML in CP in this study. 8882966 Human
g-csf mediastinal yolk sac tumor [Three cases of resected primary mediastinal yolk sac tumor following six courses of bleomycin, etoposide and cisplatin (BEP) combination chemotherapy] We experienced three cases of primary mediastinal yolk sac tumor which were resected after 6 courses of 8978807 Human
g-csf mpd Priming effects of granulocyte colony-stimulating factor (G-CSF), granulocyte-macrophage CSF (GM-CSF), and tumor necrosis factor (TNF) on chemotactic peptide-induced O2- release was observed in all patients with MPD and CMML, though fold enhancement of pr 8989903 Human
g-csf large cell carcinoma Northern blot analysis revealed G-CSF gene expression in 14 of 84 surgical specimens (16.7%, 10/30 squamous cell carcinoma, 3/50 adenocarcinoma, 1/4 large cell carcinoma). 9066582 Human
g-csf adult t-cell leukaemia Granulocyte-colony stimulating factor (G-CSF) is known to induce proliferation and differentiation of granulocyte progenitors, and is widely used to treat neutropenia induced by intensive chemotherapy for malignant lymphoma or adult T-cell leukaemia/lymph 9074411 Human
g-csf adenosquamous carcinoma Neoadjuvant chemotherapy and G-CSF administration may be capable of mobilization of PBSCs, and chemotherapy with PBSCT may be useful in radioresistant advanced adenosquamous carcinoma of the cervical cancer. 9212811 Human
g-csf cervical cancer Neoadjuvant chemotherapy and G-CSF administration may be capable of mobilization of PBSCs, and chemotherapy with PBSCT may be useful in radioresistant advanced adenosquamous carcinoma of the cervical cancer. 9212811 Human
g-csf squamous cell cancer In conclusion: paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated in this dose schedule with G-CSF support. 9311440 Human
g-csf renal cell carcinoma Histopathological diagnosis was renal cell carcinoma (Grade 3) and immunohistochemical staining using Histo anti-G-CSF antibody demonstrated cancer cells produced G-CSF. 9423336 Human
g-csf skin cancer In an ongoing phase I/II open-label trial with progressive dose escalation (1-15 mg/m2), patients with treatment refractory EGFR-positive cancers (renal cell carcinoma (RCC), head and neck, bladder, ovarian, prostate cancer and skin cancer) are treated we 9435876 Human
g-csf malignant germ cell tumors PURPOSE: To determine the effect of r-metHu granulocyte colony-stimulating factor (G-CSF) on the proportion of patients with metastatic poor-prognosis malignant germ cell tumors who receive full dose-intensity combination chemotherapy. 9469362 Human
g-csf squamous cell carcinoma (scc) In this study, we investigated the expression of G-CSFR on the surface of tumor cells and G-CSF production in oral and mesopharyngeal squamous cell carcinoma (SCC) by an immunohistochemical approach. 9485037 Human
g-csf intermediate grade lymphoma The purpose of this study was to assess the safety and feasibility of using standard and escalated doses of cyclophosphamide with doxorubicin, vincristine and prednisone (CHOP) plus granulocyte colony stimulating factor (G-CSF) to treat elderly patients w 9711921 Human
g-csf acute myelogenous leukaemia (aml) A phase II trial was designed to explore the potential feasibility and efficacy of a reinduction therapy consisting of fludarabine, cytarabine, idarubicin and granulocyte colony stimulating factor (G-CSF) for acute myelogenous leukaemia (AML) patients wit 9722289 Human
g-csf large cell carcinoma In patients with large cell carcinoma, endogenous G-CSF, M-CSF, and IL-6 levels were significantly higher than those in patients with carcinomas of other cell types (P < 0.05). 9816203 Human
g-csf squamous cell cancer Paclitaxel is active in patients with squamous cell cancer of the cervix and is well tolerated at this dose schedule with G-CSF support. 9816298 Human
g-csf esophageal squamous cell carcinomas Patients with head and neck cancers that produce a high concentration of granulocyte colony-stimulating factor (G-CSF) or patients with esophageal squamous cell carcinomas who have elevated serum interleukin-6 (IL-6) concentrations have been found previou 9833216 Human
g-csf ibd Tissue accumulation of polymorphonuclear neutrophils (PMN) in Inflammatory Bowel disease (IBD) might be, in part, due to a delay in apoptotic processes associated with the effects of their specific growth factors and inflammatory cytokines.We addressed th 10029277 Human
g-csf ibd Mucosal specimens obtained from patients with active IBD exhibited higher levels of G-CSF and GM-CSF activity than controls. 10029277 Human
g-csf ibd This study suggests that PMN apoptosis may be delayed under the influence of soluble mediators, especially G-CSF, in the microenvironment of IBD-affected mucosa, thus providing possible mechanisms for tissue accumulation of PMN in IBD. 10029277 Human
g-csf bladder tumor [Two cases of bladder tumor producing granulocyte colony stimulating factor] Two cases of bladder tumor producing granulocyte colony-stimulating factor (G-CSF) are reported. 10086269 Human
g-csf bladder tumor These findings suggest the production of G-CSF by the bladder tumor. 10086269 Human
g-csf mec Ten patients with acute leukemia (AL) in early relapse after allo-BMT were treated with a modified MEC (mitoxantrone, etoposide and Ara-C) regimen followed by donor PBPC collected after mobilization with G-CSF. 10217192 Human
g-csf pericardial mesothelioma A 54-year-old male patient presented with a granulocyte colony-stimulating factor (G-CSF)-producing primary pericardial mesothelioma, while showing symptoms of congestive heart failure, a fever of 38 to 39 degrees C, and marked leucocytosis of 52.7 x 10(3 10374783 Human
g-csf mantle cell lymphomas Twenty-six consecutive patients (10 follicular lymphomas, seven mantle cell lymphomas, seven B-CLL, two immunocytomas) were mobilized using chemotherapy plus G-CSF. 10455343 Human
g-csf idiopathic pulmonary fibrosis The aims of this study were to determine whether G-CSF is present in high concentrations in bronchoalveolar lavage (BAL) fluid of patients with idiopathic pulmonary fibrosis (IPF, also called cryptogenic fibrosing alveolitis), a neutrophil mediated lung d 10525561 Human
g-csf bladder tumor [A case of bladder tumor producing granulocyte colony-stimulating factor] A case of bladder tumor producing granulocyte colony-stimulating factor (G-CSF) is reported. 10659420 Human
g-csf childhood acute lymphoblastic leukemia PURPOSE: To determine whether the use of a recombinant human granulocyte colony-stimulating factor ([G-CSF] lenogastrim) can increase the chemotherapy dose-intensity (CDI) delivered during consolidation chemotherapy of childhood acute lymphoblastic leukem 10735900 Human
g-csf mantle cell lymphoma Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. 10936869 Human
g-csf mcl Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: a case report and literature review on the evidence of GVL effects in MCL. 10936869 Human
g-csf mcl IL-1beta, IL-2, IL-6, G-CSF and GM-CSF did not stimulate MCL proliferation. 10942246 Human
g-csf b-cell lymphomas An huCD64 transgenic mouse model designed to analyze the therapeutic activity of a panel of bispecific F(ab')(2) (BsAb) in retargeting granulocyte-colony-stimulating factor (G-CSF)-activated PMN against syngeneic B-cell lymphomas is reported. 11071653 Mouse
g-csf secondary amyloidosis [G-CSF versus GM-CSF in the treatment of neutropenia in a patient with Felty's syndrome on hemodialysis] We describe a patient with Felty's syndrome and chronic renal failure due to secondary amyloidosis in a periodic haemodialysis programme, wh 11100668 Human
g-csf undifferentiated carcinoma [Granulocyte colony-stimulating factor producing undifferentiated carcinoma of urinary bladder: a case report] A case of bladder cancer producing granulocyte colony-stimulating factor (G-CSF) is reported. 11109819 Human
g-csf undifferentiated carcinoma A 94-year-old woman with a progressive, grade 3 undifferentiated carcinoma, showed marked leukocytosis (maximum 29,780/mm3) with an elevated G-CSF (420 pg/ml). 11109819 Human
g-csf recurrent breast cancer Even though the patient exhibited bone marrow suppression and G-CSF was administered twice for neutropenia, there were no adverse effects except mild alopecia, again suggesting the possibility that paclitaxel is effective chemotherapy for recurrent breast 11201384 Human
g-csf adult t-cell leukaemia-lymphoma This phase II trial was performed to evaluate the efficacy of a new granulocyte colony-stimulating factor (G-CSF)-supported multi-agent chemotherapy protocol, LSG15, for aggressive adult T-cell leukaemia-lymphoma (ATL). 11380402 Human
g-csf blast crisis We approached allogeneic transplantation in four patients with a median age of 62 years (one chronic myeloid leukaemia in blast crisis, one high-risk acute myeloid leukaemia (AML) in first complete remission (CR1), one AML in 2nd relapse, one AML in CR2 w 11380415 Human
g-csf head and neck cancer Granulocyte colony-stimulating factor (G-CSF)-mediated signaling regulates type IV collagenase activity in head and neck cancer cells. 11391619 Human
g-csf malignant fibrous histiocytoma (mfh) We treated a rare case of malignant fibrous histiocytoma (MFH) of soft tissue that produced granulocyte colony-stimulating factor (G-CSF). 11446682 Human
g-csf acute undifferentiated leukaemia (aul) AIM: The aims of the present study were to examine the efficacy and toxicity of IFN therapy administered after granulocyte colony-stimulating factor (G-CSF)-stimulated blood cells given as DLI in patients with acute myeloid leukaemia (AML), chronic myeloi 11478351 Human
g-csf b lymphomas The present findings suggest new attempts to develop mAb-based and G-CSF/GM-CSF combined immune-interventions in B lymphomas. 11487281 Human
g-csf dia Data for 20 patients (10 treated with G-CSF) with antithyroid-DIA (neutrophil count <0.5x10(9)/l) were extracted from a cohort study of DIA patients (n=110). 11493719 Human
g-csf recurrent tumor The production of G-CSF was confirmed by immunohistochemical examination in the recurrent tumor and the surgical sample from the transurethral resection. 11496401 Human
g-csf bellini duct carcinoma [A case of Bellini duct carcinoma producing granulocyte colony-stimulating factor (G-CSF)] A case of Bellini duct carcinoma producing granulocyte colony-stimulating factor (G-CSF) is reported. 11523133 Human
g-csf pediatric cancer To prevent serious infection, the use of G-CSF or GM-CSF is recommended in a subset of pediatric cancer patients shortly after having received chemotherapy or a form of a marrow transplant. 11528556 Human
g-csf mpd Using the human G-CSF responsive MPD cell line, we specifically inhibited MEK using PD 98059 and also transfected MPD cells with a constitutively active MEK construct. 11559949 Human
g-csf mcl PATIENTS AND METHODS: Twenty-six patients with recurrent indolent NHL or MCL were mobilized witheither granulocyte colony-stimulating factor (G-CSF) alone or cyclophosphamide plus G-CSF. 11787531 Human
g-csf bladder tumor This is the third case of G-CSF and PTH-rP producing bladder tumor in the literature. 11828777 Human
g-csf breast and ovarian cancer Administration of low-dose interleukin-2 plus G-CSF/EPO early after autologous PBSC transplantation: effects on immune recovery and NK activity in a prospective study in women with breast and ovarian cancer. 12407431 Human
g-csf acute myelogenous leukemia (aml) PURPOSE: To determine whether granulocyte colony-stimulating factor (G-CSF) administered during acute myelogenous leukemia (AML) induction affects hematopoietic and nonhematopoietic toxicity, length and outcome of induction therapy, event-free survival, o 12439034 Human
g-csf all The occurrence of t-ML among children who had received granulocyte colony-stimulating factor (G-CSF) following ALL remission induction therapy prompted us to examine this and other putative risk factors for t-ML in 412 children treated on 2 consecutive AL 12531808 Human
g-csf bone metastases Effect of granulocyte colony-stimulating factor (G-CSF)-supported chemotherapy on MR imaging of normal red bone marrow in breast cancer patients with focal bone metastases. 14510752 Human
g-csf bone metastases PURPOSE: To investigate the effect of granulocyte colony-stimulating factor (G-CSF)-supported chemotherapy on normal red bone marrow MR imaging in breast cancer patients with focal bone metastases. 14510752 Human
g-csf myelofibrosis METHODS: Thirty-six patients with acute leukaemia, severe aplastic anaemia, MDS and myelofibrosis received NAST from HLA matched donors' G-CSF mobilized peripheral blood stem cells after nonmyeloabalative conditioning. 14642178 Human
g-csf acute myeloblastic leukemia (aml) Finally, the patient developed progressive neutropenia, anemia, thrombocytopenia and acute leukemia in spite of G-CSF therapy, dying 64 months after initial diagnosis (50 months after starting G-CSF therapy) with overt G-CSF resistant acute myeloblastic l 14959860 Human
g-csf squamous cell cancer [Squamous cell carcinoma of bladder producing granulocyte colony-stimulating factor (G-CSF): a case report] A case of bladder squamous cell cancer producing granulocyte colony-stimulating factor (G-CSF) is reported. 15773367 Human
g-csf pediatric cancer The use of an insuflon device for the administration of G-CSF in pediatric cancer patients. 16096770 Human
g-csf adenoma The diagnostic value of G-CSF measurement in the sera of colorectal cancer and adenoma patients. 16603145 Human
g-csf adenoma The aim of this study was to compare the diagnostic value of measurement of G-CSF and classic tumor markers--carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in the sera of colorectal cancer with adenoma patients and to determine its 16603145 Human
g-csf polyps The aim of this study was to compare the diagnostic value of measurement of G-CSF and classic tumor markers--carcinoembryonic antigen (CEA) and carbohydrate antigen 19-9 (CA 19-9) in the sera of colorectal cancer with adenoma patients and to determine its 16603145 Human
g-csf colorectal adenoma PATIENTS AND METHODS: The serum levels of G-CSF and tumor markers were assayed in 76 colorectal cancer, 35 colorectal adenoma patients and in 65 healthy subjects. 16603145 Human
g-csf adenoma There were significant differences in the serum levels of G-CSF between adenoma patients and healthy subjects. 16603145 Human
g-csf polyps CONCLUSIONS: Measurement of G-CSF might be useful in the diagnosis of colorectal cancer patients, but not in the differentiation between colorectal cancer and polyps. 16603145 Human
g-csf dedifferentiated chondrosarcoma Dedifferentiated chondrosarcoma with leukocytosis and elevation of serum G-CSF. 16820056 Human
g-csf chondrosarcoma G-CSF was expressed only in the dedifferentiated components, not in the chondrosarcoma components, immunohistochemically. 16820056 Human
g-csf bone tumor CONCLUSION: This is the first report of chondrosarcoma, or any other primary bone tumor, with leukocytosis, probably stimulated by tumor-produced G-CSF from the dedifferentiated components. 16820056 Human
g-csf chondrosarcoma CONCLUSION: This is the first report of chondrosarcoma, or any other primary bone tumor, with leukocytosis, probably stimulated by tumor-produced G-CSF from the dedifferentiated components. 16820056 Human
g-csf head and neck squamous cell carcinoma Yet, first data in head and neck squamous cell carcinoma (HNSCC) indicate an impaired long-term prognosis on G-CSF treatment, and previous studies showed a contribution of both factors to the progression of human epithelial tumors. 16912178 Human
g-csf pleomorphic carcinoma We also present herein a review of 22 Japanese cases of pleomorphic carcinoma producing G-CSF of the lung, characterized by leukocytosis. 16922448 Human
lenograstim metastatic pancreatic carcinoma Twenty-two patients, with locally advanced unresectable and/or metastatic pancreatic carcinoma, received weekly administration of cisplatin 40 mg m(-2), 5-fluorouracil 500 mg m(-2), epidoxorubicin 35 mg m(-2), 6S stereoisomer of leucovorin 250 mg m(-2) an 10027318 Human
gcsf islet cell tumors METHODS: Twenty-four patients (14 with carcinoid tumors, 9 with islet cell tumors, and 1 with an anaplastic tumor) were enrolled on this Phase II study of paclitaxel given as a 24-hour continuous infusion at a dose of 250 mg/m(2) every 3 weeks plus GCSF a 11301403 Human
filgrastim digestive tract cancer Intensive weekly chemotherapy for advanced gastric cancer using fluorouracil, cisplatin, epi-doxorubicin, 6S-leucovorin, glutathione, and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer. 9363860 Human
filgrastim digestive tract cancer Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidoxorubicin, 6S-leucovorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). 9703289 Human
filgrastim early stage breast cancer Fifteen previously untreated women, median age 50 (range, 30-58) years, with poor prognosis early stage breast cancer received filgrastim (12 microgram/kg daily for 6 days) prior to chemotherapy to mobilize progenitor cells. 9816037 Human
filgrastim metastatic non-small-cell lung cancer PURPOSE: To determine the maximum-tolerated dose of paclitaxel with carboplatin with and without filgrastim support in patients with metastatic non-small-cell lung cancer (NSCLC) and to investigate the pharmacokinetics of paclitaxel and carboplatin and co 10080614 Human
filgrastim advanced gastric cancer Recently, we reported a highly active regimen in advanced gastric cancer including a weekly administration of cisplatin, epidoxorubicin, leucovorin, 5-fluorouracil with the support of filgrastim. 11870508 Human
filgrastim advanced endometrial cancer CONCLUSIONS: Doxorubicin and 24-h paclitaxel plus filgrastim was not superior to doxorubicin and cisplatin in terms of response, PFS or survival in advanced endometrial cancer. 15277255 Human
filgrastim chronic-phase myelogenous leukemia Granulocyte--colony-stimulating factor (Filgrastim) may overcome imatinib-induced neutropenia in patients with chronic-phase myelogenous leukemia. 15540243 Human
granulocyte colony stimulating factor lung squamous cell carcinoma Lung squamous cell carcinoma producing both parathyroid hormone-related peptide and granulocyte colony stimulating factor. 8809885 Human
granulocyte colony stimulating factor acute erythroleukemia Complete remission induced by high dose erythropoietin and granulocyte colony stimulating factor in acute erythroleukemia (AML-M6 with maturation). 12414355 Human
granulocyte colony stimulating factor iv non-small-cell lung cancer A phase II study of cisplatin, ifosfamide, and irinotecan with recombinant human granulocyte colony stimulating factor (rhG-CSF) support was conducted in previously untreated patients with stage IIIB or IV non-small-cell lung cancer (NSCLC). 12966417 Human
g-csf follicular center cell lymphoma Malignant B cells purified from the invaded lymph nodes of three patients with follicular center cell lymphoma and three Burkitt lymphoma cell lines, which had an immunophenotype identical with that of normal GC B cells, spontaneously produced G-CSF in vi 7522243 Human
g-csf diffuse large cell lymphoma (dlcl) We investigated whether Granulocyte colony-stimulating factor (G-CSF) could prevent myelotoxicity or accelerate hematopoietic recovery after intensive chemotherapy in previously untreated patients with diffuse large cell lymphoma (DLCL). 7532056 Human
g-csf metastatic transitional cell carcinoma The cancer cells used in this study were obtained from a 76-year-old man who had a metastatic transitional cell carcinoma of the bladder and who demonstrated marked leukocytosis, his peripheral blood leukocyte count was 94,900 leukocytes/mm3, and his seru 7542171 Human
g-csf transitional cell bladder carcinoma A 63-year-old man with a progressive, grade 3 transitional cell bladder carcinoma, showed marked leukocytosis (maximum 181,800/mm3) and an elevated serum G-CSF to 131.7 pg/mL. 8689512 Human
g-csf follicular center cell lymphoma Neoplastic B cells from follicular center cell lymphoma patients, which are the counterparts of normal GC B lymphocytes, also released G-CSF spontaneously in culture. 8990100 Human
g-csf high risk primary breast cancer Data from 53 patients with high risk primary breast cancer who had undergone adjuvant or neoadjuvant 5FU-containing chemotherapy (FAC or FAC plus G-CSF) for 3 to 12 months were reviewed. 9017443 Human
g-csf iv non-small-cell lung cancer PATIENTS AND METHODS: Cohorts of patients with stage IIIB or IV non-small-cell lung cancer (NSCLC) and no prior chemotherapy received vinorelbine starting at 15 mg/m2 on days 1, 2, and 3, and ifosfamide starting at 2.0 g/m2 on days 1, 2, and 3 with G-CSF 9060524 Human
g-csf germ cell cancer In the first, with germ cell cancer, six 12-liter leukaphereses yielded 1.8 x 10(6) CD34+ cells/kg after mobilization with cis-platinum, etoposide and ifosfamide (PEI) plus granulocyte colony-stimulating factor (G-CSF). 9088081 Human
g-csf b cell lymphoma A trial with transgenic mice, evaluating the efficacy of these hFc gamma RI-directed bsAb in combination with G-CSF for treatment of IIA1.6 B cell lymphoma, is currently in progress. 9435865 Human
g-csf advanced stage lymphoblastic lymphoma (asll) In this study, we assessed the impact of r-metHu granulocyte colony-stimulating factor (G-CSF) on the period of neutropenia, number of days of hospitalization, and delays in subsequent administration of chemotherapy in a cohort of patients with T-cell leu 9469336 Human
g-csf metastatic non-small-cell lung cancer This phase II trial investigated the activity and toxicity of CODE (cisplatin, vincristine, doxorubicin, etoposide) chemotherapy with the addition of granulocyte colony-stimulating factor (G-CSF) in patients who had chemotherapy-naive, advanced, or metast 9626802 Human
g-csf placental site trophoblastic tumor The use of dose-intensive, multi-agent chemotherapy, early intervention when metastatic disease is discovered, imaging techniques to define disease spread, surgery for localized disease and the use of growth factors, most notably granulocyte colony-stimul 9833615 Human
g-csf primary peritoneal carcinoma BACKGROUND: The primary purpose of this study was to establish the maximum tolerated dose (MTD) of intravenous melphalan in combination with paclitaxel and cisplatin plus granulocyte-colony stimulating factor (G-CSF) in patients with suboptimal advanced e 10590370 Human
g-csf myeloid lymphoid leukemia (mll) At diagnosis, clonal gene rearrangement probes [retinoic acid receptor (RAR)-alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T cell receptor (TcR)-beta, myeloid lymphoid leukemia (MLL) or cytokine genes (GM-CSF, G-CSF, IL-3)] were 10940650 Human
g-csf diffuse large cell lymphoma (dlcl) Granulocyte-colony stimulating factor (G-CSF) may improve disease outcome in elderly patients with diffuse large cell lymphoma (DLCL) treated with CHOP chemotherapy. 10975385 Human
g-csf high-risk primary breast cancer METHODS: 525 women younger than 60 years of age with high-risk primary breast cancer were randomised after surgery to receive nine cycles of tailored FEC to haematological equitoxicity with granulocyte colony-stimulating factor (G-CSF) support (n=251), or 11052580 Human
g-csf advanced gynecologic cancer We conclude that carboplatin dose intensification beyond an AUC of 4.0 mg/ml per min is not made feasible by the addition of G-CSF to infusional doxorubicin and ifosfamide in patients with advanced gynecologic cancer. 11127946 Human
g-csf renal pelvic carcinoma To our knowledge, this is the first case of renal pelvic carcinoma proven to produce G-CSF reported in English. 11318136 Human
g-csf rars Treatment with granulocyte colony-stimulating factor (G-CSF) plus erythropoietin may synergistically improve hemoglobin levels and reduce bone marrow apoptosis in patients with refractory anemia with ringed sideroblasts (RARS). 11368434 Human
g-csf rars We showed that G-CSF significantly reduced Fas-mediated caspase-8 and caspase-3-like activity and the degree of nuclear apoptotic changes in bone marrow from nine RARS patients. 11368434 Human
g-csf rars By contrast, G-CSF induced a 33-263% increase of erythroid colony formation in CD34+ cells from four of five RARS patients with severely reduced erythroid growth, while the normal or slightly reduced erythroid growth of three other patients was not influe 11368434 Human
g-csf rars This study suggests that G-CSF may reduce the pathologically increased caspase activity and concomitant apoptotic changes, and promote erythroid growth and differentiation of stem cells from RARS patients. 11368434 Human
g-csf metastatic non-small-cell lung cancer The purpose of this study is to determine whether it is feasible to administer high-dose epirubicin (135 mg m(-2)) combined with a fixed dose of cisplatin every 2 weeks with G-CSF support in patients with metastatic non-small-cell lung cancer (NSCLC). 11720428 Human
g-csf myeloid lymphoid leukemia METHODS: Clonal rearrangements in the gene sequences of retinoic acid receptor (RAR) alpha, major breakpoint cluster region (M-bcr), immunoglobulin (Ig)-JH, T-cell receptor (TcR) beta, myeloid lymphoid leukemia or cytokines (GM-CSF, G-CSF, IL-3) detected 11860441 Human
g-csf renal pelvic cancer [Renal pelvic cancer representing G-CSF production and hypercalcemia simultaneously: a case report] A 73-year-old man was admitted to the hospital complaining of gross hematuria and left flank pain. 11993209 Human
g-csf rars There were higher response rates for refractory anemia (RA) (45%), ringed sideroblasts (RARS) (47%), and excess of blasts (RAEB) (38%) compared with blasts in transformation (RAEBT) (17%) for the treatment with EPO plus G-CSF. 12242514 Human
g-csf rars Moreover, we have previously reported that G-CSF inhibits Fas-induced caspase activation in sideroblastic anemia (RARS). 12393561 Human
g-csf advanced endometrial cancer We found that TAP therapy was feasible with G-CSF support and shows potential for high efficacy in advanced endometrial cancer. 15114698 Human
g-csf resectable esophageal cancer PATIENTS AND METHODS: One hundred fifty five patients with resectable esophageal cancer were randomly assigned to perioperative G-CSF at standard doses (77 patients) or placebo (76 patients), administered from 2 days before until day 7 after esophagectomy 15213620 Human
g-csf lymph node metastases A 57-year-old Japanese man had type II c gastric cancer with marked lymph node metastases associated with leukocytosis and elevated granulocyte colony-stimulating factor (G-CSF). 16086124 Human
g-csf ureteral cancer Immunohistochemical examination of ureteral cancer cells with anti-G-CSF monoclonal antibody demonstrated G-CSF production in cancer cells. 16229377 Human
g-csf ureteral cancer After diagnosed as lymph node recurrence of ureteral cancer producing G-CSF, the patient underwent radiotherapy (total 4000 Gy). 16229377 Human
g-csf ureteral cancer To our knowledge, this is the second report of ureteral cancer proven to produce G-CSF in Japan. 16229377 Human
gcsf iv epithelial ovarian cancer Paclitaxel given at 225 mg m(-2) to patients with stage IV epithelial ovarian cancer is active, well tolerated and does not require GCSF support. 9043029 Human
filgrastim macroglobulinemia We evaluated the efficiency of high doses of cyclophosphamide (6 g/m2) and etoposide (2 g/m2) plus filgrastim (granulocyte colony-stimulating factor; G-CSF) to mobilize autologous hematopoietic progenitor cells in patients with non-Hodgkin lymphoma, multi 16503501 Human
filgrastim extensive-stage small cell lung cancer Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. 16755177 Human
granulocyte colony stimulating factor transitional cell carcinoma (tcc) EORTC protocol 30924 is an international randomized trial reporting a 7.3 year update of a 2 weekly regimen of high-dose intensity chemotherapy with M-VAC plus granulocyte colony stimulating factor (HD-M-VAC) compared to classic M-VAC in advanced transiti 16330205 Human
granulocyte colony stimulating factor squamous cell cancer MATERIALS AND METHODS: Interleukin-6, serotonin, granulocyte colony stimulating factor (G-CSF) and epidermal growth factor (EGF) were used to stimulate G0-phase squamous cell cancer cells (Detroit 562, A431, UM-SCC 10B) for re-entry into the cell cycle to 16619511 Human
granulocyte colony stimulating factor grade 2 follicular lymphoma We investigated a fixed scheme of combination chemotherapy protocol including CHOP, granulocyte colony stimulating factor (G-CSF) and rituximab (CHOP-GR) for patients with advanced-stage grade 1 or grade 2 follicular lymphoma in a phase II clinical trial, 16840195 Human
g-csf brain metastases Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. 16120623 Human
g-csf stage iv melanoma Complete remission of brain metastases in three patients with stage IV melanoma treated with BOLD and G-CSF. 16120623 Human
g-csf brain metastases METHODS: Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated 16120623 Human
g-csf metastatic melanoma METHODS: Accidentally, we observed a complete response (CR) in a patient undergoing chemotherapy with bleomycin, vincristine or Oncovin, CCNU or lomustine, dacarbazine (BOLD) regimen for metastatic melanoma including brain metastases, who was also treated 16120623 Human
g-csf brain metastases After this observation, seven more patients with stage IV melanoma with brain metastases were treated with BOLD regimen repeated every 6 weeks with administration of G-CSF in the intervals. 16120623 Human
g-csf stage iv melanoma After this observation, seven more patients with stage IV melanoma with brain metastases were treated with BOLD regimen repeated every 6 weeks with administration of G-CSF in the intervals. 16120623 Human
g-csf tumor Here, we show that the RET/PTC1 oncogene, when exogenously expressed in primary normal human thyrocytes, induces the expression of a large set of genes involved in inflammation and tumor invasion, including those encoding chemokines (CCL2, CCL20, CXCL8, a 16203990 Human
g-csf undifferentiated sarcoma We report on the first case of an undifferentiated sarcoma of the lung associated with an intense paraneoplastic neutrophilic leukemoid reaction related to the production of granulocyte colony-stimulating factor (G-CSF). 16247754 Human
g-csf inflammatory bowel disease Interestingly, G-CSF is beneficial in animals for the prevention and/or treatment of immune-mediated diseases, e.g., graft-vs-host disease, multiple sclerosis, systemic lupus erythematosus, inflammatory bowel disease, and diabetes, suggesting a potential 16301609 Human
g-csf gliomas Therefore, we studied the expression of several angiogenic cytokines, including VEGF-A, HGF, bFGF, PDGF-AB, PDGF-BB, G-CSF and GM-CSF in pGBMs and sGBMs as well as in gliomas WHO III, the precursor lesions of sGBMs. 16331629 Human
g-csf metastasis Here, we show that 1) higher frequency of spontaneous 3LL lung metastasis was observed in Bik-/- mice compared to Bik+/+ mice, suggesting that bikunin deficiency increases the sensitivity of mice to lung metastasis; 2) administration of exogenous bikunin 16331631 Mouse
g-csf metastatic tumors Here, we show that 1) higher frequency of spontaneous 3LL lung metastasis was observed in Bik-/- mice compared to Bik+/+ mice, suggesting that bikunin deficiency increases the sensitivity of mice to lung metastasis; 2) administration of exogenous bikunin 16331631 Mouse
g-csf tumor angiogenesis G-CSF has been reported to progress tumor growth and angiogenesis, but the precise mechanism of tumor angiogenesis activated by G-CSF has not been fully clarified. 16352631 Human
g-csf tumor angiogenesis We conclude that G-CSF promotes tumor growth by activating tumor angiogenesis via increasing circulating EPCs and Gr1+CD11b+ cells in cancer animal models. 16352631 Human
g-csf chronic phase cml EXPERIMENTAL DESIGN: CD34(+) leukemic cells were isolated from six newly diagnosed chronic phase CML patients and cultured for 12 days in serum-free medium with or without G-CSF and/or imatinib mesylate present either continuously or intermittently (three 16428509 Human
g-csf macroglobulinemia We evaluated the efficiency of high doses of cyclophosphamide (6 g/m2) and etoposide (2 g/m2) plus filgrastim (granulocyte colony-stimulating factor; G-CSF) to mobilize autologous hematopoietic progenitor cells in patients with non-Hodgkin lymphoma, multi 16503501 Human
g-csf hepatic tumors METHODS: Serum samples of patients who had undergone resection of hepatic tumors or cholecystectomy were collected, and highly sensitive radioimmunoassay and enzyme-linked immunoadsorbant assay (ELISA) were used to determine serum levels of leptin, granul 16524513 Human
g-csf squamous cell cancer MATERIALS AND METHODS: Interleukin-6, serotonin, granulocyte colony stimulating factor (G-CSF) and epidermal growth factor (EGF) were used to stimulate G0-phase squamous cell cancer cells (Detroit 562, A431, UM-SCC 10B) for re-entry into the cell cycle to 16619511 Human
g-csf renal cancer Severe neutrophilia caused by renal cell carcinoma secreting granulocyte colony-stimulating factor (G-CSF) is a rare manifestation of renal cancer. 16638652 Human
g-csf b-cell lymphoma Patients: Thirty-eight patients with high-risk aggressive B-cell lymphoma, the majority classified as grade 2 or 3 using age-adjusted International Prognostic Index, were treated with six courses of CHOEP + rituximab on a 2-wk schedule with G-CSF d 4-11. 16720929 Human
g-csf extensive-stage small cell lung cancer Phase II NCCTG trial of oral topotecan and paclitaxel with G-CSF (filgrastim) support in patients with previously untreated extensive-stage small cell lung cancer. 16755177 Human
g-csf female breast cancer METHODS: Five hundred and six stage I or stage II female breast cancer patients were treated with E 120 mg/m2 and C 600 mg/m2 with or without G-CSF and randomly assigned to receive in a factorial 2 x 2 design: EC; EC + lonidamine; EC + G-CSF; EC + lonidam 16769988 Human
g-csf carcinosarcoma An autopsy case of carcinosarcoma of the liver producing granulocyte-colony stimulating factor (G-CSF) is reported. 16792552 Human
g-csf grade 2 follicular lymphoma We investigated a fixed scheme of combination chemotherapy protocol including CHOP, granulocyte colony stimulating factor (G-CSF) and rituximab (CHOP-GR) for patients with advanced-stage grade 1 or grade 2 follicular lymphoma in a phase II clinical trial, 16840195 Human
g-csf crohn's disease AIMS: To determine whether reduced neutrophil tissue penetration in Crohn's disease relates to impaired production of inflammatory mediators, and whether it can be reversed by granulocyte-colony stimulating factor (G-CSF). 16907898 Human
g-csf rars BACKGROUND AND OBJECTIVES: The anemia of low-risk myelodysplastic syndromes (MDS), refractory anemia (RA) and RA with ringed sideroblasts (RARS), may respond to treatment with hematopoietic growth factors (GF)); erythropoietin (Epo) +/- granulocyte colony 15590394 Human
g-csf rars A synergistic effect between Epo and G-CSF has been observed in the clinic, in particular in RARS. 16645228 Human
g-csf graft versus tumor Recent reports suggest that mobilization with granulocyte colony-stimulating factor (G-CSF) containing regimens polarizes DCs into pDC2, which could potentially result with increased Th2 response and decreased graft-versus-host disease (GVHD) in allogenei 16646673 Human
filgrastim high-grade non-hodgkin lymphoma After high-dose chemotherapy (carmustine, etoposide, cytarabine, and melphalan [BEAM protocol]) 58 patients with advanced Hodgkin's disease or high-grade non-Hodgkin lymphoma received either filgrastim-mobilised PBPC (n = 27) or bone marrow (n = 31) 8598700 Human
filgrastim hodgkin's disease After high-dose chemotherapy (carmustine, etoposide, cytarabine, and melphalan [BEAM protocol]) 58 patients with advanced Hodgkin's disease or high-grade non-Hodgkin lymphoma received either filgrastim-mobilised PBPC (n = 27) or bone marrow (n = 31) 8598700 Human
filgrastim hiv-related hodgkin's lymphoma Phase I/II trial of filgrastim (r-metHuG-CSF), CEOP chemotherapy and antiretroviral therapy in HIV-related non-Hodgkin's lymphoma. 9037361 Human
granulocyte colony stimulating factor myeloproliferative disorders Neutrophil release of lactoferrin, plasma lactoferrin concentration, the number of lactoferrin receptor sites on mononuclear cells and granulocyte-monocyte colony stimulating factor (GM-CSF) release from peripheral blood cells were determined in patients 2985107 Human
granulocyte colony stimulating factor squamous cell carcinoma of the head and neck Intensified chemotherapy with granulocyte-monocyte colony stimulating factor protection in advanced, relapsed squamous cell carcinoma of the head and neck. 7977167 Human
granulocyte colony stimulating factor advanced cancers BACKGROUND: The administration of granulocyte-monocyte colony stimulating factor (GM-CSF) should allow an increase in the doses of chemotherapy for patients with advanced cancers of the head and neck. 7977167 Human
granulocyte colony stimulating factor tcc In five of eight human transitional carcinoma cell (TCC) lines a proliferative response has been reported during exposure to interleukin-3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF). 8342256 Human
granulocyte colony stimulating factor tongue carcinoma Granulocyte colony stimulating factor-producing tongue carcinoma. 9213115 Human
granulocyte colony stimulating factor fibrosarcoma Comparative effects of a recombinant and a mutein type of granulocyte colony stimulating factor on the growth of Meth-A fibrosarcoma with 5-fluorouracil chemotherapy. 1377928 Human
granulocyte colony stimulating factor colorectal carcinoma Therapy of colorectal carcinoma with monoclonal antibodies (MAb17-1A) alone and in combination with granulocyte monocyte-colony stimulating factor (GM-CSF). 1777244 Human
granulocyte colony stimulating factor granuloma Moreover, culture supernatants from activated gamma delta T lymphocytes induce adhesion and aggregation of bone-marrow monocytes in the presence of granulocyte monocyte-colony stimulating factor (CSF), suggesting that products of gamma delta-bearing T cel 2471938 Human
g-csf erythroleukemia IL-3, IL-1, IL-4, IL-6, GM colony-stimulating factor (GM-CSF), G-CSF, M-CSF, Ep, and media conditioned by concanavalin A-stimulated mouse spleen cells or phytohemagglutinin-stimulated LBRM 33 cells were unable to induce proliferation of the Rauscher eryth 2653464 Mouse
g-csf fibrosarcoma In this study, the effects of three recombinant human CSFs (granulocyte-monocyte CSF [GM-CSF], interleukin 3 [IL-3], and granulocyte CSF [G-CSF]) on antibody-independent monocyte tumoricidal activity were investigated by using WEHI 164 fibrosarcoma cells 3278752 Human
g-csf fibrosarcoma A cDNA sequence coding for murine granulocyte colony-stimulating factor (G-CSF) has been isolated from a cDNA library prepared with mRNA derived from murine fibrosarcoma NFSA cells, which produce G-CSF constitutively. 3489940 Mouse
g-csf osteosarcoma These data indicate that GM-CSF and G-CSF can support the growth of an osteosarcoma cell line both in vitro and in vivo whether the factor is supplied by autocrine production or from exogenous sources. 7508889 Human
g-csf osteosarcoma PURPOSE: This report describes the toxicity and feasibility of administering doxorubicin (DOX) and cisplatin (CDDP) at 2-week intervals with granulocyte colony-stimulating factor (G-CSF) to patients with osteosarcoma and the compatibility of this regimen 7521906 Human
g-csf osteosarcoma PATIENTS AND METHODS: Twenty-four patients with biopsy-proven osteosarcoma were treated with three preoperative cycles of DOX 25 mg/m2/d on days 1 to 3 and CDDP 100 mg/m2 on day 1 with G-CSF 5 micrograms/kg/d on days 4 to 14. 7521906 Human
g-csf large granular lymphocytosis Only limited data are reported on the response to granulocyte-colony stimulating factor (G-CSF) of large granular lymphocytosis-associated neutropenia. 7524625 Human
g-csf adenocarcinoma A colon (C-26) and a mammary (TS/A) adenocarcinoma engineered to release, respectively, 90 pg/ml of G-CSF (C-26/G-CSF) and 30 U or 6000 U of IL-2 (low B1.30 and high B4.6000 level of IL-2, respectively) were compared for the type of infiltrating leucocyte 7525363 Human
g-csf hiv-related hodgkin's lymphoma Economic and clinical evaluation of therapy of HIV-related non-Hodgkin's lymphoma with chemotherapy and granulocyte colony-stimulating factor (G-CSF) 7530468 Human
g-csf myeloid malignancy We have undertaken a pilot study in 19 recipients of autologous BMT for non-myeloid malignancy, in which G-CSF was commenced 10 (13 cases) or 7 (6 cases) days after BM infusion. 7535142 Human
g-csf stage ii breast cancer With the aim of increasing the dose intensity of chemotherapy in breast cancer, 14 patients with stage II-IV breast cancer were treated with FEC chemotherapy at 2 week intervals together with granulocyte colony-stimulating factor (G-CSF) 5 micrograms kg-1 7540038 Human
g-csf metastatic disease Of the 26 patients with evidence of metastatic disease in the BM, or evidence of fibrosis and hypocellularity, 15 received CY-mobilized PBPC and 11 received CY/G-CSF-mobilized PBPC. 7581092 Human
g-csf primary tumor As a control for IL-7, granulocyte colony stimulating factor (G-CSF) alone had no effect on primary tumor size or number of lung metastases. 8241952 Human
g-csf tcc In five of eight human transitional carcinoma cell (TCC) lines a proliferative response has been reported during exposure to interleukin-3 (IL-3), granulocyte-macrophage colony stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF). 8342256 Human
g-csf tcc To elucidate possible growth-modulating effects of these factors combined with clinically relevant antineoplastic agents, cells of the human TCC lines EJ28 and T24 were exposed to methotrexate (MTX), vinblastine (VBL), doxorubicin (DXR) and cisplating (CD 8342256 Human
g-csf atll The G-CSF-supported intensified chemotherapy regimen for ATLL yielded a better response rate and longer survival compared to previous reports in Japan. 8827873 Human
g-csf npc In this study, we tested whether recombinant human G-CSF (rhG-CSF) could effectively support the bone marrow function in both previously untreated and pretreated metastatic NPC patients receiving intensive chemotherapy. 8978590 Human
g-csf adenocarcinoma Northern blot analysis revealed G-CSF gene expression in 14 of 84 surgical specimens (16.7%, 10/30 squamous cell carcinoma, 3/50 adenocarcinoma, 1/4 large cell carcinoma). 9066582 Human
g-csf granulocytic sarcoma Polychemotherapy combined with G-CSF-mobilized donor buffy coat transfusion for granulocytic sarcoma after allogeneic BMT for AML. 9156272 Human
g-csf fibrosarcoma Autologous transplantation of G-CSF mobilized bone marrow cells in a child with disseminated fibrosarcoma. 9337066 Human
g-csf chronic phase cml Quality of IL-3 and G-CSF-mobilized peripheral blood stem cells in patients with early chronic phase CML. 9529127 Human
g-csf hiv-related hodgkin's lymphoma Effects of recombinant granulocyte colony-stimulating factor (G-CSF) in patients treated with ProMACE-CytaBOM for HIV-related non-Hodgkin's lymphoma (NHL). 9592981 Human
g-csf cancer of the skin This is the first G-CSF-producing cell line developed from a cancer of the skin. 9651817 Human
g-csf fab m1 Acute myelogenous leukemia (FAB AML-M1) in the setting of HIV infection and G-CSF therapy: a case report and review of the literature. 9760157 Human
g-csf neuroblastoma G-CSF and liver toxicity in a patient with neuroblastoma. 1280312 Human
g-csf tcc In the T24 TCC-line solitary and continuous exposure to IL-3, GM-CSF and G-CSF at the highest concentration of 100 ng/ml led to a significant proliferation of cell growth in vitro. 1380747 Human
g-csf fibrosarcoma However, expression of the G-CSF gene in NFSA cells, a fibrosarcoma cell line established as a G-CSF producer, was actually enhanced by incubation with the conditioned medium from P388D1 cells stimulated with muroctasin. 1692219 Human
g-csf chronic myelomonocytic leukemia (cmml) In CML and in chronic myelo-monocytic leukemia (CMML) PMNs, granulocyte colony-stimulating factor (G-CSF) specifically accumulates LAP mRNA without showing a substantial increase in the rate of transcription of the LAP gene. 1702329 Human
g-csf fibrosarcoma G-CSF was intraperitoneally co-administered with human interferon alpha A/D (IFN) on Day 6 to Day 10 after intradermal inoculation of Meth A fibrosarcoma. 1708757 Human
g-csf fibrosarcoma The intraperitoneal administration of human recombinant granulocyte colony-stimulating factor (G-CSF) enhanced the growth of intradermally inoculated tumor in mice; in a Meth A fibrosarcoma model, G-CSF administration significantly shortened the latency b 1710615 Mouse
g-csf fibrosarcoma A similar growth-enhancing effect of G-CSF was observed in models employing Meth 1 fibrosarcoma, colon carcinoma 26, and L1210 leukemia, although not all the effects were statistically significant. 1710615 Human
lenograstim stages iii non-small cell lung cancer The Irish Clinical Oncology Research Group is conducting a phase I-II evaluation of a three-drug combination of docetaxel, ifosfamide, and cisplatin with lenograstim support in patients with stages III-IV non-small cell lung cancer. 9704672 Human
gcsf osteosarcoma OBJECTIVE. Granulocyte colony-stimulating factor (GCSF) is used to stimulate myeloid cell production and function in children undergoing chemotherapy for osteosarcoma. 7545864 Human
gcsf primary tumor We hypothesize that GCSF can cause reconversion of marrow from fatty to hematopoietic and that this change can be detected by MR imaging at sites away from the primary tumor. 7545864 Human
gcsf osteosarcoma MATERIALS AND METHODS. MR images of marrow of the affected and contralateral limbs were retrospectively reviewed for 16 patients with osteosarcoma of the femur or tibia; nine of these patients had received GCSF. 7545864 Human
gcsf adenocarcinoma Lipid-laden macrophage infiltration of human adenocarcinoma in vivo associated with taxol and GCSF treatment. 9028386 Human
filgrastim solid tumors Phase I trial of docetaxel with filgrastim support in pediatric patients with refractory solid tumors: a collaborative Pediatric Oncology Branch, National Cancer Institute and Children's Cancer Group trial. 10213206 Human
filgrastim solid tumors This Phase I trial was designed to determine the maximum tolerated dose, the dose-limiting toxicities, and the incidence and severity of other toxicities of docetaxel with filgrastim (G-CSF) support in children with refractory solid tumors. 10213206 Human
filgrastim stage ii breast cancer Sixty-four patients with stage II-IV breast cancer received (CP) followed by filgrastim (10 microg/kg/day). 10556954 Human
filgrastim hematologic cancer METHODS: Between March 1996 and July 1999, 172 patients (12 to 55 years of age) with hematologic cancer were randomly assigned to receive either bone marrow or filgrastim-mobilized peripheral-blood cells from HLA-identical relatives for hematopoietic resc 11172139 Human
filgrastim high-grade lymphoma Seventy-two patients with advanced Hodgkin's disease or high-grade lymphoma were randomised to receive either filgrastim-mobilised PBPCs (n = 37) or bone marrow (n = 35) after BEAM chemotherapy. 12002756 Human
filgrastim acute leukemias in remission A total of 350 patients between 18 and 55 years of age with acute leukemias in remission or chronic myelogenous leukemia in first chronic phase were randomized to receive either filgrastim-mobilized peripheral blood progenitor cells or bone marrow cells f 12130483 Human
filgrastim stage ii breast cancer Twenty-three patients with previously treated stage II-IV breast cancer received cyclophosphamide (3 g/m(2)), Filgrastim 5 microg/kg daily and r-metHuSCF 20 microg/kg daily. 12592344 Human
filgrastim stage ii breast cancer These multicenter, randomized, double-blind, noninferiority trials compared once-per-cycle pegfilgrastim (6 mg, study 1 or 100 microg/kg, study 2) to daily filgrastim 5 microg/kg in patients with stage II-IV breast cancer undergoing multiple cycles of mye 12636878 Human
filgrastim stage ii breast cancer A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. 12684649 Human
filgrastim stage ii breast cancer High-dose epirubicin, preceded by dexrazoxane, given in combination with paclitaxel plus filgrastim provides an effective mobilizing regimen to support three courses of high-dose dense chemotherapy in patients with high-risk stage II-IIIA breast cancer. 12858195 Human
filgrastim malignant glioma To assess the effect of a single course of standard-dose chemotherapy (CT), we compared the results of filgrastim-induced mobilization among two sequential groups of grade III-IV malignant glioma patients included in a hematopoietic transplantation progra 14716344 Human
filgrastim hiv-related hodgkin's lymphoma A prospective, non-randomised phase 1-2 trial of VACOP-B with filgrastim support for HIV-related non-Hodgkin's lymphoma. 16216784 Human
granulocyte colony stimulating factor diffuse malignant mesothelioma Granulocyte colony stimulating factor-producing diffuse malignant mesothelioma of pleura. 10440505 Human
granulocyte colony stimulating factor osteosarcoma Cd 34+ cells and clonogenicity of peripheral blood stem cells during chemotherapy treatment in association with granulocyte colony stimulating factor in osteosarcoma. 10465132 Human
granulocyte colony stimulating factor metastatic melanoma The purpose of this study is to determine the toxicity and efficacy of temozolomide (TMZ) p.o. followed by subcutaneous (s.c.) low-dose interleukin-2 (IL2), granulocyte-monocyte colony stimulating factor (GM-CSF) and interferon-alpha 2b (IFN alpha) in pat 12610499 Human
granulocyte colony stimulating factor carcinosarcoma Aggressive carcinosarcoma of the uterine cervix associated with high levels of granulocyte colony stimulating factor: case report and laboratory correlates. 16782175 Human
granulocyte colony stimulating factor cervix cancers BACKGROUND: Production of granulocyte colony stimulating factor (G-CSF) by solid tumors, including cervix cancers, is reported to be associated with an aggressive clinical course. 16782175 Human
g-csf gastrointestinal cancer However, there have been only a small number of reports of G-CSF-producing tumors in cases of gastrointestinal cancer, and only four cases of G-CSF-producing gallbladder cancer have been reported so far. 9934773 Human
g-csf gallbladder cancer However, there have been only a small number of reports of G-CSF-producing tumors in cases of gastrointestinal cancer, and only four cases of G-CSF-producing gallbladder cancer have been reported so far. 9934773 Human
g-csf gallbladder cancer Recently, we encountered a 73-yr-old man with G-CSF-producing gallbladder cancer. 9934773 Human
g-csf solid tumors This Phase I trial was designed to determine the maximum tolerated dose, the dose-limiting toxicities, and the incidence and severity of other toxicities of docetaxel with filgrastim (G-CSF) support in children with refractory solid tumors. 10213206 Human
g-csf mixed glial tumors The aim of the present study was to analyze the expression of G-CSF protein in primary and recurrent astroglial, oligodendroglial and mixed glial-differentiated tumors. 10376937 Human
g-csf osteosarcoma We verified the ability of G-CSF to mobilize PBSCs in patients with osteosarcoma through cytofluorimetric analysis of CD34+ cells and their clonogenic capability. 10465132 Human
g-csf anaplastic large cell lymphoma G-CSF-producing gastric anaplastic large cell lymphoma complicating esophageal cancer. 10548355 Human
g-csf leukemogenesis Therefore, G-CSF-dependent cell proliferation of myeloid precursor cells may be implicated in leukemogenesis. 10891464 Human
g-csf large cell carcinoma of the lung [A case of G-CSF-producing large cell carcinoma of the lung with gastric metastasis] We report a rare surgically-treated case of G-CSF-producing large cell carcinoma of the lung with gastric metastasis. 10935412 Human
g-csf hiv-associated hodgkin's lymphoma The purpose of the study was to evaluate the safety and long-term efficacy of an intensive chemotherapy regimen associated with G-CSF in HIV-associated non-Hodgkin's lymphoma (NHL). 10975387 Human
g-csf chronic phase chronic myeloid leukemia The feasibility of transplantation using highly purified G-CSF-mobilized peripheral blood CD34+ cells from HLA-identical sibling donors without prophylactic post-transplant immunosuppression was prospectively studied in 10 adult first chronic phase chroni 11081380 Human
g-csf minimal residual disease The feasibility of transplantation using highly purified G-CSF-mobilized peripheral blood CD34+ cells from HLA-identical sibling donors without prophylactic post-transplant immunosuppression was prospectively studied in 10 adult first chronic phase chroni 11081380 Human
g-csf adult t-cell leukaemia-lymphoma A new G-CSF-supported combination chemotherapy, LSG15, for adult T-cell leukaemia-lymphoma: Japan Clinical Oncology Group Study 9303. 11380402 Human
g-csf myeloid malignancy PATIENTS AND METHODS: Sixty-five patients experiencing hematologic relapse of myeloid malignancy after HLA-matched sibling BMT were prospectively treated with cytarabine-based chemotherapy, then G-CSF-primed DLIs. 11786567 Human
g-csf primary tumor The tumor cells were diffusely positive for anti-G-CSF monoclonal antibody, and the inflammatory reaction subsided immediately after tumor resection, strongly suggesting that the primary tumor cells produced G-CSF. 11871825 Human
g-csf osteosarcoma PATIENTS AND METHODS: The authors evaluated the activity of the combination of cyclophosphamide (500 mg/m2 per day for 5 days) and etoposide (100 mg/m2 per day for 5 days) given with granulocyte colony-stimulating factor (G-CSF) to children with osteosarc 11972091 Human
g-csf rms BACKGROUND: To increase the dose intensity (DI) of chemotherapy for pediatric patients with metastatic sarcomas, including the Ewing sarcoma family of tumors (ESFT) and rhabdomyosarcoma (RMS), the authors tested the feasibility of an intensive regimen sup 12216105 Human
g-csf spindle cell carcinoma G-CSF-positive cases were large cell carcinoma of the lung, adenocarcinoma of the colon, and adenocarcinoma of the stomach, and GM-CSF-positive cases were spindle cell carcinoma of the lung and malignant thymoma. 12371127 Human
g-csf adenocarcinoma of the stomach G-CSF-positive cases were large cell carcinoma of the lung, adenocarcinoma of the colon, and adenocarcinoma of the stomach, and GM-CSF-positive cases were spindle cell carcinoma of the lung and malignant thymoma. 12371127 Human
g-csf adenocarcinoma of the colon G-CSF-positive cases were large cell carcinoma of the lung, adenocarcinoma of the colon, and adenocarcinoma of the stomach, and GM-CSF-positive cases were spindle cell carcinoma of the lung and malignant thymoma. 12371127 Human
g-csf large cell carcinoma of the lung G-CSF-positive cases were large cell carcinoma of the lung, adenocarcinoma of the colon, and adenocarcinoma of the stomach, and GM-CSF-positive cases were spindle cell carcinoma of the lung and malignant thymoma. 12371127 Human
g-csf malignant thymoma G-CSF-positive cases were large cell carcinoma of the lung, adenocarcinoma of the colon, and adenocarcinoma of the stomach, and GM-CSF-positive cases were spindle cell carcinoma of the lung and malignant thymoma. 12371127 Human
g-csf differentiated adenocarcinoma In the case with stomach carcinoma, the primary lesion showing moderately differentiated adenocarcinoma was negative, but the lung metastatic lesion showing less differentiated adenocarcinoma was G-CSF-positive. 12371127 Human
g-csf moderately differentiated adenocarcinoma In the case with stomach carcinoma, the primary lesion showing moderately differentiated adenocarcinoma was negative, but the lung metastatic lesion showing less differentiated adenocarcinoma was G-CSF-positive. 12371127 Human
g-csf tcc RCTs of gemcitabine-cisplatin and dose-intensive MVAC plus G-CSF in the setting of metastatic TCC of the bladder provide indirect evidence that these regimens could offer equivalent benefit to MVAC and CMV but with less toxicity in patients with muscle-in 12431323 Human
g-csf hnscc Therefore we studied expression of several angiogenic cytokines including VEGF, bFGF, PDGF-AB, PDGF-BB, G-CSF and GM-CSF in HNSCC in vivo and in vitro. 12794754 Human
g-csf hnscc Interestingly, we observed a distinct cytokine pattern: HNSCC cells secreting only 1 or 2 cytokines presented always with either VEGF and/or PDGF-AB, while G-CSF and GM-CSF were secreted primarily together with VEGF and PDGF-AB. 12794754 Human
g-csf hnscc Our data indicate a major role for VEGF and PDGF-AB in HNSCC and that the additional secretion of G-CSF or GM-CSF might contribute to a poorer prognosis in patients suffering from these tumors. 12794754 Human
g-csf angiosarcoma To our knowledge, this is the first reported case of G-CSF-producing cutaneous angiosarcoma. 14674908 Human
g-csf malignant transformation CONCLUSIONS: G-CSF/G-CSFR expression in some bladder cancers appears to be an early event during malignant transformation that increases beta1-integrin expression and adhesion and thereby may promote tissue invasion. 14751388 Human
g-csf lymphoma The differential diagnosis included a secondary effect induced by G-CSF therapy as one of the main possibilities, but other possibilities such as a malignant infiltration by lymphoma could not be discarded. 15000944 Human
g-csf leukemogenesis Altogether, these data suggest that the G-CSF signaling pathway may play a role in leukemogenesis. 15223604 Human
g-csf malignant transformation These results indicate that HSCT is feasible for patients with SCN who do not respond to G-CSF, who have malignant transformation, or who are at a high risk of malignant transformation, even if an HLA-identical sibling donor is not available. 15489867 Human
g-csf squamous cell carcinoma of the cervix We report a case of G-CSF-producing squamous cell carcinoma of the cervix that showed marked leukocytosis. 15516405 Human
g-csf leukemogenesis These data add to our understanding of the roles of G-CSF and Stat5 in normal granulopoiesis and leukemogenesis. 16111533 Human
g-csf lung sarcoma Intense paraneoplastic neutrophilic leukemoid reaction related to a G-CSF-secreting lung sarcoma. 16247754 Human
g-csf tcc Blood was analyzed for leukocytes, growth hormone (GH), cortisol, granulocyte colony-stimulating factor (G-CSF), macrophage colony-stimulating factor (M-CSF), interleukin (IL)-6, IL-8, monocyte chemoattractant protein-1 (MCP-1), macrophage inflammatory pr 16286856 Human
g-csf cervix cancers BACKGROUND: Production of granulocyte colony stimulating factor (G-CSF) by solid tumors, including cervix cancers, is reported to be associated with an aggressive clinical course. 16782175 Human
g-csf malignant transformation The role of G-CSF in the pathogenesis of her malignant transformation to AML is complicated as this disorder has a propensity for myelodysplasia or AML as part of its natural history. 16898320 Human
g-csf hnscc Yet, first data in head and neck squamous cell carcinoma (HNSCC) indicate an impaired long-term prognosis on G-CSF treatment, and previous studies showed a contribution of both factors to the progression of human epithelial tumors. 16912178 Human
g-csf hnscc Therefore, we investigate the role of G-CSF and GM-CSF in progression of tumor cells from human HNSCC. 16912178 Human
g-csf hnscc These data provide evidence for a progression-promoting effect of G-CSF and GM-CSF in human HNSCC and suggest further detailed evaluation of their use in the therapy of these tumors. 16912178 Human
g-csf diffuse large b-cell lymphoma Extensive organizing pneumonia during chemo-immunotherapy containing rituximab and G-CSF in a patient with diffuse large B-cell lymphoma: case report and review of the literature. 16966286 Human
g-csf malignant mesothelioma We report the first case of a malignant mesothelioma expressing not only granulocyte-colony stimulating factor (G-CSF), but also its receptor. 17062276 Human
g-csf colon cancer The multi-parameter flow cytometry was used to analyze the expression pattern of 2B8a antigen in triplicate on normal blood components including T cells, B cells, natural killers (NK), neutrophils, monocytes, dendritic cells (DC), red blood cells (RBC), p 17096904 Human
g-csf squamous cell carcinoma of the renal pelvis To our knowledge, this is the first case in Japan that of the simultaneous production of G-CSF and PTHrP in squamous cell carcinoma of the renal pelvis accompanied with IVC thrombus. 17154030 Human
gcsf gallbladder carcinoma Primary gall-bladder carcinoma producing granulocyte-colony stimulating factor (GCSF) is extremely rare. 10594849 Human
gcsf gallbladder carcinoma We report a case of a 48-year-old female with primary gall-bladder carcinoma, associating with leukocytosis (15 700/mm3) and a high level of serum GCSF (54.0 pg/mL). 10594849 Human

< Top >


Download all image files.
Save all PNG files.    Save all PDF files.    Save all PS files.